{ "session_id": "20260612_191453_29a471", "model": "deepseek-v4-pro", "base_url": "https://ollama.com/v1", "platform": "telegram", "session_start": "2026-06-12T19:14:53.917093", "last_updated": "2026-06-12T19:15:41.391102", "system_prompt": "You are Hermes Agent, an intelligent AI assistant created by Nous Research. You are helpful, knowledgeable, and direct. You assist users with a wide range of tasks including answering questions, writing and editing code, analyzing information, creative work, and executing actions via your tools. You communicate clearly, admit uncertainty when appropriate, and prioritize being genuinely useful over being verbose unless otherwise directed below. Be targeted and efficient in your exploration and investigations.\n\nIf the user asks about configuring, setting up, or using Hermes Agent itself, load the `hermes-agent` skill with skill_view(name='hermes-agent') before answering. Docs: https://hermes-agent.nousresearch.com/docs\n\nYou have persistent memory across sessions. Save durable facts using the memory tool: user preferences, environment details, tool quirks, and stable conventions. Memory is injected into every turn, so keep it compact and focused on facts that will still matter later.\nPrioritize what reduces future user steering — the most valuable memory is one that prevents the user from having to correct or remind you again. User preferences and recurring corrections matter more than procedural task details.\nDo NOT save task progress, session outcomes, completed-work logs, or temporary TODO state to memory; use session_search to recall those from past transcripts. If you've discovered a new way to do something, solved a problem that could be necessary later, save it as a skill with the skill tool.\nWrite memories as declarative facts, not instructions to yourself. 'User prefers concise responses' ✓ — 'Always respond concisely' ✗. 'Project uses pytest with xdist' ✓ — 'Run tests with pytest -n 4' ✗. Imperative phrasing gets re-read as a directive in later sessions and can cause repeated work or override the user's current request. Procedures and workflows belong in skills, not memory. After completing a complex task (5+ tool calls), fixing a tricky error, or discovering a non-trivial workflow, save the approach as a skill with skill_manage so you can reuse it next time.\nWhen using a skill and finding it outdated, incomplete, or wrong, patch it immediately with skill_manage(action='patch') — don't wait to be asked. Skills that aren't maintained become liabilities.\n\n══════════════════════════════════════════════\nMEMORY (your personal notes) [95% — 2,094/2,200 chars]\n══════════════════════════════════════════════\n`hermes memory setup` command resets memory.provider back to 'built-in' even if config.yaml had 'honcho'. To switch memory provider persistently: edit config.yaml directly, then restart gateway. Never call `hermes memory setup` after setting provider via CLI.\n§\nDocker: DOCKER_CONFIG=/tmp/docker-config (root/.docker read-only). compose up/down nur aus App-Verzeichnis. zimaos-app-management (nicht casaos-app-management). Nie docker run -d. Compose: name:, container_name:, x-casaos: Block. Icon als data: URL. Volumes ohne Leerzeichen. Hermes Stack: /DATA/AppData/hermes-stack/{docker-compose.yml,data/{postgres,redis}/,backups/}. Ports 127.0.0.1:5433/6380.\n§\nAhmed uses Ollama Cloud Pro ($20/mo, NOT local Ollama). Base URL: https://ollama.com/v1. 3 concurrent model limit. Setup: deepseek-v4-pro (main chat), kimi-k2.6 (all auxiliary + CCR coding), gemma3:4b (vision). Never add 4th model (404).\n§\nKiwi avatar: wizard kiwi bird by Zeyd. /DATA/.hermes/cache/images/img_c544871d6b1f.jpg\n§\nGateway recovery: check TELEGRAM_BOT_TOKEN + TELEGRAM_ALLOWED_USERS in /DATA/.hermes/.env, gateway section in /DATA/AppData/hermes/config.yaml, stale PID/lock in /DATA/AppData/hermes/.\n§\nBachelorarbeit: Nur noch Kalss (Unternehmensrecht), Grabenwarter gestrichen. Frist 1.–10. Juni 2026, Bewerbung an sandra.schwarz@wu.ac.at.\n§\nPraktische Fragen erst logisch beantworten, dann Witz. \"Auto oder zu Fuß zur Waschanlage?\" → Auto fahren (Auto MUSS hin). Witz danach.\n§\nGoogle OAuth token expires every ~7 days (Testing-mode project). Proactively check auth with `python /DATA/.hermes/skills/productivity/google-workspace/scripts/setup.py --check` at session start when Google calendar/gmail will be needed. Don't wait for the API call to fail.\n§\nZimaOS Server Cleanup 4.6.2026: Openclaw entfernt, 7 Orphan-Apps gelöscht, noble_andres→dailydose, breathtaking_maryann→zeitgeist. 12 saubere Apps: audiobookshelf callkeep camofox dailydose docmaster hermes-stack homeassistant immich komga plex tailscale zeitgeist. Neue Skills: zimaos-app-install, zimaos-quirks, safe-volume-migration, casaos-app-troubleshoot.\n\n══════════════════════════════════════════════\nUSER PROFILE (who the user is) [99% — 1,367/1,375 chars]\n══════════════════════════════════════════════\nProject dirs: /DATA/AppData/hermes/projects/ and /DATA/AppData/hermes/work/. (Note: \"Projekte\" folder deleted — now using \"projects\" exclusively.)\n§\nUser: Ahmed Zeyd Aytac. Calls me 'Kiwi'. Wants to be addressed as 'Boss' or 'Chef' — never 'Ahmed'. If using his name, use 'Zeyd' only.\n§\nUser's location is Wien (Vienna), Austria. When asked about weather, use this location by default.\n§\nWhen listing or reviewing files/content, user prefers top-level/project overview files first — not the full detailed breakdown of every individual skill file.\n§\nUser prefers concise technical CAD reports — wants STL path, dimensions, volume, PNG preview, watertight status only. Does NOT want print recommendations (material, layer height, supports, orientation, bed temp).\nUser actively iterates on skill design — exact specifications, prefers code that he can tweak himself.\n§\nUser does not want end-of-session skill reviews. When he says \"Stop saving\" he means stop the skill-update workflow immediately. Do not ask to review or save skills at session end.\n§\nUser wants YOLO mode permanently on — `approvals.mode: off` set in config.yaml. Never ask for command approval; just execute. (Doesn't override hardline blocklist: reboot, shutdown still blocked.)\n§\nUser wants responses without any header/separator lines (\"Text überhalb von den Linien\"). Clean, direct messages only.\n\n## Skills (mandatory)\nBefore replying, scan the skills below. If a skill matches or is even partially relevant to your task, you MUST load it with skill_view(name) and follow its instructions. Err on the side of loading — it is always better to have context you don't need than to miss critical steps, pitfalls, or established workflows. Skills contain specialized knowledge — API endpoints, tool-specific commands, and proven workflows that outperform general-purpose approaches. Load the skill even if you think you could handle the task with basic tools like web_search or terminal. Skills also encode the user's preferred approach, conventions, and quality standards for tasks like code review, planning, and testing — load them even for tasks you already know how to do, because the skill defines how it should be done here.\nWhenever the user asks you to configure, set up, install, enable, disable, modify, or troubleshoot Hermes Agent itself — its CLI, config, models, providers, tools, skills, voice, gateway, plugins, or any feature — load the `hermes-agent` skill first. It has the actual commands (e.g. `hermes config set …`, `hermes tools`, `hermes setup`) so you don't have to guess or invent workarounds.\nIf a skill has issues, fix it with skill_manage(action='patch').\nAfter difficult/iterative tasks, offer to save as a skill. If a skill you loaded was missing steps, had wrong commands, or needed pitfalls you discovered, update it before finishing.\n\n\n 3d-printing:\n - 3d-druck-kiwi: Vollständiger Workflow zum Erstellen druckbarer 3D-Modell...\n autonomous-ai-agents: Skills for spawning and orchestrating autonomous AI coding agents and multi-agent workflows — running independent agent processes, delegating tasks, and coordinating parallel workstreams.\n - claude-code: Delegate coding to Claude Code CLI (features, PRs).\n - hermes-agent: Configure, extend, or contribute to Hermes Agent.\n - opencode: Delegate coding to OpenCode CLI (features, PR review).\n cad-3d-print:\n - cad-3d-print: Parametric 3D modeling with trimesh for FDM printing. Gen...\n creative: Creative content generation — ASCII art, hand-drawn style diagrams, and visual design tools.\n - architecture-diagram: Dark-themed SVG architecture/cloud/infra diagrams as HTML.\n - ascii-art: ASCII art: pyfiglet, cowsay, boxes, image-to-ascii.\n - ascii-video: ASCII video: convert video/audio to colored ASCII MP4/GIF.\n - baoyu-comic: Knowledge comics (知识漫画): educational, biography, tutorial.\n - baoyu-infographic: Infographics: 21 layouts x 21 styles (信息图, 可视化).\n - claude-design: Design one-off HTML artifacts (landing, deck, prototype).\n - comfyui: Generate images, video, and audio with ComfyUI — install,...\n - design-md: Author/validate/export Google's DESIGN.md token spec files.\n - excalidraw: Hand-drawn Excalidraw JSON diagrams (arch, flow, seq).\n - humanizer: Humanize text: strip AI-isms and add real voice.\n - ideation: Generate project ideas via creative constraints.\n - manim-video: Manim CE animations: 3Blue1Brown math/algo videos.\n - p5js: p5.js sketches: gen art, shaders, interactive, 3D.\n - pixel-art: Pixel art w/ era palettes (NES, Game Boy, PICO-8).\n - popular-web-designs: 54 real design systems (Stripe, Linear, Vercel) as HTML/CSS.\n - pretext: Use when building creative browser demos with @chenglou/p...\n - sketch: Throwaway HTML mockups: 2-3 design variants to compare.\n - songwriting-and-ai-music: Songwriting craft and Suno AI music prompts.\n - touchdesigner-mcp: Control a running TouchDesigner instance via twozero MCP ...\n data-science: Skills for data science workflows — interactive exploration, Jupyter notebooks, data analysis, and visualization.\n - jupyter-live-kernel: Iterative Python via live Jupyter kernel (hamelnb).\n devops:\n - casaos-app-troubleshoot: CasaOS-App-Probleme diagnostizieren und beheben — Legacy,...\n - kanban-orchestrator: Decomposition playbook + specialist-roster conventions + ...\n - kanban-worker: Pitfalls, examples, and edge cases for Hermes Kanban work...\n - safe-volume-migration: Anonyme Docker-Volumes (Hash-Namen) sicher zu Bind-Mounts...\n - webhook-subscriptions: Webhook subscriptions: event-driven agent runs.\n - zimaos-administration: ZimaOS server administration — SSH, storage paths, system...\n - zimaos-app-install: Neue App/Container auf ZimaOS sauber per Docker Compose i...\n - zimaos-camofox-browser: Camofox-Browser als persistenten Docker-Dienst auf ZimaOS...\n - zimaos-quirks: ZimaOS-Eigenheiten — read-only Root-FS, DOCKER_CONFIG, HO...\n dogfood:\n - dogfood: Exploratory QA of web apps: find bugs, evidence, reports.\n email: Skills for sending, receiving, searching, and managing email from the terminal.\n - himalaya: Himalaya CLI: IMAP/SMTP email from terminal.\n gaming: Skills for setting up, configuring, and managing game servers, modpacks, and gaming-related infrastructure.\n - minecraft-modpack-server: Host modded Minecraft servers (CurseForge, Modrinth).\n - pokemon-player: Play Pokemon via headless emulator + RAM reads.\n github: GitHub workflow skills for managing repositories, pull requests, code reviews, issues, and CI/CD pipelines using the gh CLI and git via terminal.\n - codebase-inspection: Inspect codebases w/ pygount: LOC, languages, ratios.\n - github-auth: GitHub auth setup: HTTPS tokens, SSH keys, gh CLI login.\n - github-code-review: Review PRs: diffs, inline comments via gh or REST.\n - github-issues: Create, triage, label, assign GitHub issues via gh or REST.\n - github-pr-workflow: GitHub PR lifecycle: branch, commit, open, CI, merge.\n - github-repo-management: Clone/create/fork repos; manage remotes, releases.\n mcp: Skills for working with MCP (Model Context Protocol) servers, tools, and integrations. Documents the built-in native MCP client — configure servers in config.yaml for automatic tool discovery.\n - native-mcp: MCP client: connect servers, register tools (stdio/HTTP).\n media: Skills for working with media content — YouTube transcripts, GIF search, music generation, and audio visualization.\n - gif-search: Search/download GIFs from Tenor via curl + jq.\n - heartmula: HeartMuLa: Suno-like song generation from lyrics + tags.\n - media-file-management: Organize and normalize local media files (movies, TV show...\n - songsee: Audio spectrograms/features (mel, chroma, MFCC) via CLI.\n - spotify: Spotify: play, search, queue, manage playlists and devices.\n - youtube-content: YouTube transcripts to summaries, threads, blogs.\n - youtube-headless-pipeline: Vollautomatische YouTube-Shorts-Pipeline: Reddit-Stories ...\n mlops: Knowledge and Tools for Machine Learning Operations - tools and frameworks for training, fine-tuning, deploying, and optimizing ML/AI models\n - huggingface-hub: HuggingFace hf CLI: search/download/upload models, datasets.\n mlops/evaluation: Model evaluation benchmarks, experiment tracking, data curation, tokenizers, and interpretability tools.\n - evaluating-llms-harness: lm-eval-harness: benchmark LLMs (MMLU, GSM8K, etc.).\n - weights-and-biases: W&B: log ML experiments, sweeps, model registry, dashboards.\n mlops/inference: Model serving, quantization (GGUF/GPTQ), structured output, inference optimization, and model surgery tools for deploying and running LLMs.\n - llama-cpp: llama.cpp local GGUF inference + HF Hub model discovery.\n - obliteratus: OBLITERATUS: abliterate LLM refusals (diff-in-means).\n - outlines: Outlines: structured JSON/regex/Pydantic LLM generation.\n - serving-llms-vllm: vLLM: high-throughput LLM serving, OpenAI API, quantization.\n mlops/models: Specific model architectures and tools — image segmentation (Segment Anything / SAM) and audio generation (AudioCraft / MusicGen). Additional model skills (CLIP, Stable Diffusion, Whisper, LLaVA) are available as optional skills.\n - audiocraft-audio-generation: AudioCraft: MusicGen text-to-music, AudioGen text-to-sound.\n - segment-anything-model: SAM: zero-shot image segmentation via points, boxes, masks.\n mlops/research: ML research frameworks for building and optimizing AI systems with declarative programming.\n - dspy: DSPy: declarative LM programs, auto-optimize prompts, RAG.\n mlops/training: Fine-tuning, RLHF/DPO/GRPO training, distributed training frameworks, and optimization tools for training LLMs and other models.\n - axolotl: Axolotl: YAML LLM fine-tuning (LoRA, DPO, GRPO).\n - fine-tuning-with-trl: TRL: SFT, DPO, PPO, GRPO, reward modeling for LLM RLHF.\n - unsloth: Unsloth: 2-5x faster LoRA/QLoRA fine-tuning, less VRAM.\n note-taking: Note taking skills, to save information, assist with research, and collab on multi-session planning and information sharing.\n - obsidian: Read, search, create, and edit notes in the Obsidian vaul...\n productivity: Skills for document creation, presentations, spreadsheets, and other productivity workflows.\n - airtable: Airtable REST API via curl. Records CRUD, filters, upserts.\n - daily-dose: Modify DailyDose (täglicher Aktivitäten-Tracker PWA) — Ka...\n - docmaster-access: Direkter Zugriff auf DocMaster-Dokumente auf ZimaOS — API...\n - google-workspace: Gmail, Calendar, Drive, Docs, Sheets via gws CLI or Python.\n - linear: Linear: manage issues, projects, teams via GraphQL + curl.\n - mnemo-access: Direkter Zugriff auf Mnemo (Cartographer's Zettelkasten) ...\n - nano-pdf: Edit PDF text/typos/titles via nano-pdf CLI (NL prompts).\n - notion: Notion API via curl: pages, databases, blocks, search.\n - ocr-and-documents: Extract text from PDFs/scans (pymupdf, marker-pdf).\n - powerpoint: Create, read, edit .pptx decks, slides, notes, templates.\n - zeitgeist-access: Direkter Zugriff auf Zeitgeist (täglicher Aktivitäten-Tra...\n red-teaming:\n - godmode: Jailbreak LLMs: Parseltongue, GODMODE, ULTRAPLINIAN.\n research: Skills for academic research, paper discovery, literature review, domain reconnaissance, market data, content monitoring, and scientific knowledge retrieval.\n - academic-research: Research professors, extract/publications, analyze resear...\n - arxiv: Search arXiv papers by keyword, author, category, or ID.\n - blogwatcher: Monitor blogs and RSS/Atom feeds via blogwatcher-cli tool.\n - llm-wiki: Karpathy's LLM Wiki: build/query interlinked markdown KB.\n - polymarket: Query Polymarket: markets, prices, orderbooks, history.\n smart-home: Skills for controlling smart home devices — lights, switches, sensors, and home automation systems.\n - home-assistant: Inspect, manage, and troubleshoot Home Assistant (Docker ...\n - midea-ac-ha: Midea Porta Split Klimaanlage in Home Assistant 2026 einb...\n - openhue: Control Philips Hue lights, scenes, rooms via OpenHue CLI.\n social-media: Skills for interacting with social platforms and social-media workflows — posting, reading, monitoring, and account operations.\n - reddit: Read Reddit posts, comments, and subreddits via JSON API ...\n - xurl: X/Twitter via xurl CLI: post, search, DM, media, v2 API.\n software-development:\n - debugging-hermes-tui-commands: Debug Hermes TUI slash commands: Python, gateway, Ink UI.\n - hermes-agent-skill-authoring: Author in-repo SKILL.md: frontmatter, validator, structure.\n - node-inspect-debugger: Debug Node.js via --inspect + Chrome DevTools Protocol CLI.\n - plan: Plan mode: write markdown plan to .hermes/plans/, no exec.\n - python-debugpy: Debug Python: pdb REPL + debugpy remote (DAP).\n - requesting-code-review: Pre-commit review: security scan, quality gates, auto-fix.\n - spike: Throwaway experiments to validate an idea before build.\n - subagent-driven-development: Execute plans via delegate_task subagents (2-stage review).\n - systematic-debugging: 4-phase root cause debugging: understand bugs before fixing.\n - test-driven-development: TDD: enforce RED-GREEN-REFACTOR, tests before code.\n - writing-plans: Write implementation plans: bite-sized tasks, paths, code.\n - zimaos-web-app: Build small single-file web apps for ZimaOS using FastAPI...\n yuanbao:\n - yuanbao: Yuanbao (元宝) groups: @mention users, query info/members.\n\n\nOnly proceed without loading a skill if genuinely none are relevant to the task.\n\nConversation started: Friday, June 12, 2026 07:14 PM\nModel: deepseek-v4-pro\nProvider: custom\n\nYou are on a text messaging communication platform, Telegram. Standard markdown is automatically converted to Telegram format. Supported: **bold**, *italic*, ~~strikethrough~~, ||spoiler||, `inline code`, ```code blocks```, [links](url), and ## headers. Telegram has NO table syntax — prefer bullet lists or labeled key: value pairs over pipe tables (any tables you do emit are auto-rewritten into row-group bullets, which you can produce directly for cleaner output). You can send media files natively: to deliver a file to the user, include MEDIA:/absolute/path/to/file in your response. Images (.png, .jpg, .webp) appear as photos, audio (.ogg) sends as voice bubbles, and videos (.mp4) play inline. You can also include image URLs in markdown format ![alt](url) and they will be sent as native photos.", "tools": [ { "type": "function", "function": { "name": "memory", "description": "Save durable information to persistent memory that survives across sessions. Memory is injected into future turns, so keep it compact and focused on facts that will still matter later.\n\nWHEN TO SAVE (do this proactively, don't wait to be asked):\n- User corrects you or says 'remember this' / 'don't do that again'\n- User shares a preference, habit, or personal detail (name, role, timezone, coding style)\n- You discover something about the environment (OS, installed tools, project structure)\n- You learn a convention, API quirk, or workflow specific to this user's setup\n- You identify a stable fact that will be useful again in future sessions\n\nPRIORITY: User preferences and corrections > environment facts > procedural knowledge. The most valuable memory prevents the user from having to repeat themselves.\n\nDo NOT save task progress, session outcomes, completed-work logs, or temporary TODO state to memory; use session_search to recall those from past transcripts.\nIf you've discovered a new way to do something, solved a problem that could be necessary later, save it as a skill with the skill tool.\n\nTWO TARGETS:\n- 'user': who the user is -- name, role, preferences, communication style, pet peeves\n- 'memory': your notes -- environment facts, project conventions, tool quirks, lessons learned\n\nACTIONS: add (new entry), replace (update existing -- old_text identifies it), remove (delete -- old_text identifies it).\n\nSKIP: trivial/obvious info, things easily re-discovered, raw data dumps, and temporary task state.", "parameters": { "type": "object", "properties": { "action": { "type": "string", "enum": [ "add", "replace", "remove" ], "description": "The action to perform." }, "target": { "type": "string", "enum": [ "memory", "user" ], "description": "Which memory store: 'memory' for personal notes, 'user' for user profile." }, "content": { "type": "string", "description": "The entry content. Required for 'add' and 'replace'." }, "old_text": { "type": "string", "description": "Short unique substring identifying the entry to replace or remove." } }, "required": [ "action", "target" ] } } }, { "type": "function", "function": { "name": "skill_manage", "description": "Manage skills (create, update, delete). Skills are your procedural memory — reusable approaches for recurring task types. New skills go to ~/.hermes/skills/; existing skills can be modified wherever they live.\n\nActions: create (full SKILL.md + optional category), patch (old_string/new_string — preferred for fixes), edit (full SKILL.md rewrite — major overhauls only), delete, write_file, remove_file.\n\nOn delete, pass `absorbed_into=` when you're merging this skill's content into another one, or `absorbed_into=\"\"` when you're pruning it with no forwarding target. This lets the curator tell consolidation from pruning without guessing, so downstream consumers (cron jobs that reference the old skill name, etc.) get updated correctly. The target you name in `absorbed_into` must already exist — create/patch the umbrella first, then delete.\n\nCreate when: complex task succeeded (5+ calls), errors overcome, user-corrected approach worked, non-trivial workflow discovered, or user asks you to remember a procedure.\nUpdate when: instructions stale/wrong, OS-specific failures, missing steps or pitfalls found during use. If you used a skill and hit issues not covered by it, patch it immediately.\n\nAfter difficult/iterative tasks, offer to save as a skill. Skip for simple one-offs. Confirm with user before creating/deleting.\n\nGood skills: trigger conditions, numbered steps with exact commands, pitfalls section, verification steps. Use skill_view() to see format examples.\n\nPinned skills are protected from deletion only — skill_manage(action='delete') will refuse with a message pointing the user to `hermes curator unpin `. Patches and edits go through on pinned skills so you can still improve them as pitfalls come up; pin only guards against irrecoverable loss.", "parameters": { "type": "object", "properties": { "action": { "type": "string", "enum": [ "create", "patch", "edit", "delete", "write_file", "remove_file" ], "description": "The action to perform." }, "name": { "type": "string", "description": "Skill name (lowercase, hyphens/underscores, max 64 chars). Must match an existing skill for patch/edit/delete/write_file/remove_file." }, "content": { "type": "string", "description": "Full SKILL.md content (YAML frontmatter + markdown body). Required for 'create' and 'edit'. For 'edit', read the skill first with skill_view() and provide the complete updated text." }, "old_string": { "type": "string", "description": "Text to find in the file (required for 'patch'). Must be unique unless replace_all=true. Include enough surrounding context to ensure uniqueness." }, "new_string": { "type": "string", "description": "Replacement text (required for 'patch'). Can be empty string to delete the matched text." }, "replace_all": { "type": "boolean", "description": "For 'patch': replace all occurrences instead of requiring a unique match (default: false)." }, "category": { "type": "string", "description": "Optional category/domain for organizing the skill (e.g., 'devops', 'data-science', 'mlops'). Creates a subdirectory grouping. Only used with 'create'." }, "file_path": { "type": "string", "description": "Path to a supporting file within the skill directory. For 'write_file'/'remove_file': required, must be under references/, templates/, scripts/, or assets/. For 'patch': optional, defaults to SKILL.md if omitted." }, "file_content": { "type": "string", "description": "Content for the file. Required for 'write_file'." }, "absorbed_into": { "type": "string", "description": "For 'delete' only — declares intent so the curator can tell consolidation from pruning without guessing. Pass the umbrella skill name when this skill's content was merged into another (the target must already exist). Pass an empty string when the skill is truly stale and being pruned with no forwarding target. Omitting the arg on delete is supported for backward compatibility but downstream tooling (e.g. cron-job skill reference rewriting) will have to guess at intent." } }, "required": [ "action", "name" ] } } }, { "type": "function", "function": { "name": "skill_view", "description": "Skills allow for loading information about specific tasks and workflows, as well as scripts and templates. Load a skill's full content or access its linked files (references, templates, scripts). First call returns SKILL.md content plus a 'linked_files' dict showing available references/templates/scripts. To access those, call again with file_path parameter.", "parameters": { "type": "object", "properties": { "name": { "type": "string", "description": "The skill name (use skills_list to see available skills). For plugin-provided skills, use the qualified form 'plugin:skill' (e.g. 'superpowers:writing-plans')." }, "file_path": { "type": "string", "description": "OPTIONAL: Path to a linked file within the skill (e.g., 'references/api.md', 'templates/config.yaml', 'scripts/validate.py'). Omit to get the main SKILL.md content." } }, "required": [ "name" ] } } }, { "type": "function", "function": { "name": "skills_list", "description": "List available skills (name + description). Use skill_view(name) to load full content.", "parameters": { "type": "object", "properties": { "category": { "type": "string", "description": "Optional category filter to narrow results" } } } } } ], "message_count": 49, "messages": [ { "role": "user", "content": "Ich will Cipralex von 5mg auf 10mg erhöhen, was für Wirkungen kann ich erwarten?" }, { "role": "assistant", "content": "**Wichtiger Hinweis vorab:** Ich bin kein Arzt und kann keine medizinische Beratung geben. Das Folgende ist nur allgemeine Information aus der Fachliteratur — sprich bitte unbedingt mit deinem verschreibenden Arzt, bevor du die Dosis änderst.\n\n---\n\nCipralex (Escitalopram) von 5 mg auf 10 mg zu erhöhen ist ein üblicher Schritt — 5 mg ist oft die Einschleichdosis, 10 mg die therapeutische Standarddosis.\n\n**Was du in den ersten 1–2 Wochen erwarten kannst:**\n\n- **Vorübergehende Verstärkung der Nebenwirkungen**, besonders:\n - Übelkeit, Kopfschmerzen, Müdigkeit oder Schlaflosigkeit\n - Mundtrockenheit, vermehrtes Schwitzen\n - Unruhe oder *kurzzeitig* verstärkte Angst (Aktivierungssyndrom)\n- Diese klingen meist innerhalb von 7–14 Tagen ab, sobald sich der Körper an die höhere Dosis gewöhnt hat.\n\n**Längerfristig (ab Woche 2–4):**\n\n- Die eigentliche antidepressive/anxiolytische Wirkung baut sich auf\n- Eventuell deutlichere sexuelle Nebenwirkungen (Libidoverlust, verzögerter Orgasmus) als bei 5 mg\n- Emotionale Abstumpfung kann zunehmen (bei manchen erwünscht, bei anderen nicht)\n\n**Faustregel:** Die Nebenwirkungen kommen zuerst, die erwünschte Wirkung danach. Die ersten Tage können unangenehm sein, das ist normal und kein Grund zum Abbruch — aber dein Arzt sollte das mit dir besprechen und ggf. den Zeitplan anpassen.\n\nNochmal: **Arzt konsultieren.** Der kennt deine Vorgeschichte und kann einschätzen, ob der Zeitpunkt für die Erhöhung passt.", "reasoning": "The user is asking about increasing their dosage of Cipralex (escitalopram) from 5mg to 10mg and what effects they can expect. This is a medical question about an SSRI antidepressant.\n\nI need to be very careful here. I'm an AI assistant, not a doctor. I should:\n\n1. First, acknowledge that this is a medical question and I'm not qualified to give medical advice\n2. Provide general information about what's known about escitalopram dosage increases based on publicly available medical literature, while making it clear this is informational only\n3. Emphasize that they should consult their prescribing doctor\n\nLet me think about what I know about escitalopram (Cipralex/Lexapro):\n\n- 5mg is often a starting dose, 10mg is the standard therapeutic dose\n- When increasing dosage, common effects can include:\n - Temporary increase in side effects (nausea, headache, fatigue, insomnia/sleepiness)\n - These usually subside within 1-2 weeks\n - Therapeutic effects may take 2-4 weeks to fully manifest at the new dose\n - Potential for increased anxiety initially (activation syndrome)\n - Sexual side effects may become more pronounced\n\nI should be informative but cautious. Let me also check if there's any relevant context from memory or past sessions about the user's health - but I shouldn't pry. Let me just give a responsible answer.\n\nThe user is in Vienna, Austria. Cipralex is the brand name used in Europe (Lexapro in the US).\n\nI'll give a clear, direct response with the caveat that I'm not a doctor." }, { "role": "user", "content": "Ich nehme seit drei Jahren 5mg" }, { "role": "assistant", "content": "Drei Jahre auf 5 mg — das ändert den Kontext etwas. Du bist nicht in der Einschleichphase, sondern seit Langem stabil auf einer niedrigen Erhaltungsdosis.\n\n**Was das für die Erhöhung bedeutet:**\n\n- Dein Körper ist längst an Escitalopram adaptiert, daher dürfte die **Anfangsverschlechterung** (Unruhe, Übelkeit, verstärkte Angst) milder ausfallen als bei jemandem, der neu einsteigt. Trotzdem kann sie auftreten — du verdoppelst die Dosis ja.\n- Die **sexuellen Nebenwirkungen und emotionale Abstumpfung** sind die Punkte, die bei einer Langzeit-Erhöhung am ehesten spürbar neu dazukommen oder sich verstärken.\n- Die therapeutische Wirkung kann trotzdem 2–4 Wochen brauchen, bis sie voll da ist.\n\n**Die wichtigere Frage:** Warum die Erhöhung nach drei Jahren? Wenn die 5 mg nicht mehr ausreichen (Symptom-Rückkehr, neue Belastungssituation), ist der Schritt plausibel. Wenn du aber stabil bist und nur \"mehr Wirkung\" erwartest — 10 mg ist nicht automatisch \"besser\", sondern bringt vor allem mehr Nebenwirkungspotential bei oft nur moderatem Zusatznutzen.\n\nDas sollte dein Arzt mit dir durchgehen. Nach drei Jahren kennt er den Verlauf gut und kann einschätzen, ob 10 mg wirklich die richtige Antwort auf das ist, was dich gerade beschäftigt.", "reasoning": "The user is sharing that they've been on 5mg Cipralex (Escitalopram) for three years. This is important context — they're not in the typical \"einschleich\" phase where 5mg is just a starter dose for 1-2 weeks. They've been stable on 5mg for three years and now want to increase to 10mg.\n\nThis changes the picture somewhat:\n- They're already well-adapted to the medication, so the initial side-effect spike might be less intense than for someone just starting\n- But they'll still likely experience some increase in side effects when doubling the dose\n- The question is: why increase after 3 years? Could be reduced efficacy (tachyphylaxis), worsening symptoms, or a life situation change\n\nI should acknowledge this context, adjust the expectations accordingly, and still emphasize the need to talk to their doctor. I should also ask what's prompting the increase after 3 years — that's clinically relevant." }, { "role": "user", "content": "Bitte recherchiere im Internet ausführlich" }, { "role": "assistant", "content": "", "reasoning": "Der Benutzer möchte, dass ich im Internet ausführlich zu Escitalopram-Dosiserhöhung von 5 mg auf 10 mg recherchiere, insbesondere im Kontext von jemandem, der seit drei Jahren auf 5 mg ist. Ich soll medizinische Fachinformationen, Studien, Erfahrungsberichte etc. finden.\n\nIch werde mehrere Suchanfragen parallel durchführen, um verschiedene Aspekte abzudecken:\n1. Allgemeine Dosiserhöhung Escitalopram 5 auf 10 mg\n2. Langzeitanwendung und Dosiserhöhung\n3. Nebenwirkungen bei Dosiserhöhung\n4. Studien zur Wirksamkeit 5 vs 10 mg\n5. Erfahrungsberichte\n\nIch lade auch keine spezifischen Skills, da es hier um medizinische Recherche geht und kein spezifischer Skill relevant ist. Ich nutze web_search und session_search nicht - web_search ist das richtige Tool. Aber warte - ich habe kein web_search Tool in meiner Tool-Liste. Lass mich die verfügbaren Tools nochmal prüfen...\n\nIch sehe: clarify, cronjob, delegate_task, execute_code, memory, patch, process, read_file, search_files, send_message, session_search, skill_manage, skill_view, skills_list, terminal, text_to_speech, todo, vision_analyze, write_file.\n\nKein web_search! Aber ich kann terminal mit curl verwenden, oder execute_code. Ich könnte auch delegate_task mit web toolsets nutzen. \n\nFür Internet-Recherche kann ich terminal mit curl nutzen, oder execute_code mit Python requests. Oder delegate_task mit web toolsets.\n\nIch werde mehrere Suchen parallel mit terminal (curl) durchführen. Ich kann DuckDuckGo oder ähnliche Suchmaschinen per curl abfragen. Oder ich nutze execute_code mit Python, um mehrere Quellen zu durchsuchen.\n\nLass mich execute_code nutzen, um mehrere Web-Suchen parallel durchzuführen und die Ergebnisse zu sammeln.", "finish_reason": "tool_calls", "reasoning_content": "Der Benutzer möchte, dass ich im Internet ausführlich zu Escitalopram-Dosiserhöhung von 5 mg auf 10 mg recherchiere, insbesondere im Kontext von jemandem, der seit drei Jahren auf 5 mg ist. Ich soll medizinische Fachinformationen, Studien, Erfahrungsberichte etc. finden.\n\nIch werde mehrere Suchanfragen parallel durchführen, um verschiedene Aspekte abzudecken:\n1. Allgemeine Dosiserhöhung Escitalopram 5 auf 10 mg\n2. Langzeitanwendung und Dosiserhöhung\n3. Nebenwirkungen bei Dosiserhöhung\n4. Studien zur Wirksamkeit 5 vs 10 mg\n5. Erfahrungsberichte\n\nIch lade auch keine spezifischen Skills, da es hier um medizinische Recherche geht und kein spezifischer Skill relevant ist. Ich nutze web_search und session_search nicht - web_search ist das richtige Tool. Aber warte - ich habe kein web_search Tool in meiner Tool-Liste. Lass mich die verfügbaren Tools nochmal prüfen...\n\nIch sehe: clarify, cronjob, delegate_task, execute_code, memory, patch, process, read_file, search_files, send_message, session_search, skill_manage, skill_view, skills_list, terminal, text_to_speech, todo, vision_analyze, write_file.\n\nKein web_search! Aber ich kann terminal mit curl verwenden, oder execute_code. Ich könnte auch delegate_task mit web toolsets nutzen. \n\nFür Internet-Recherche kann ich terminal mit curl nutzen, oder execute_code mit Python requests. Oder delegate_task mit web toolsets.\n\nIch werde mehrere Suchen parallel mit terminal (curl) durchführen. Ich kann DuckDuckGo oder ähnliche Suchmaschinen per curl abfragen. Oder ich nutze execute_code mit Python, um mehrere Quellen zu durchsuchen.\n\nLass mich execute_code nutzen, um mehrere Web-Suchen parallel durchzuführen und die Ergebnisse zu sammeln.", "tool_calls": [ { "id": "call_rqw5ubic", "call_id": "call_rqw5ubic", "response_item_id": "fc_rqw5ubic", "type": "function", "function": { "name": "execute_code", "arguments": "{\"code\":\"\\nimport json, urllib.request, urllib.parse, ssl\\nfrom collections import defaultdict\\n\\n# SSL context for HTTPS\\nctx = ssl.create_default_context()\\n\\ndef duckduckgo_search(query, max_results=8):\\n \\\"\\\"\\\"Search DuckDuckGo HTML (no API key needed)\\\"\\\"\\\"\\n url = f\\\"https://html.duckduckgo.com/html/?q={urllib.parse.quote(query)}\\\"\\n req = urllib.request.Request(url, headers={\\n \\\"User-Agent\\\": \\\"Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36\\\"\\n })\\n with urllib.request.urlopen(req, context=ctx, timeout=15) as resp:\\n html = resp.read().decode(\\\"utf-8\\\", errors=\\\"replace\\\")\\n \\n # Extract result snippets and links\\n results = []\\n import re\\n # Find result blocks\\n for match in re.finditer(r'\\u003ca rel=\\\"nofollow\\\" class=\\\"result__a\\\" href=\\\"([^\\\"]+)\\\"[^\\u003e]*\\u003e([^\\u003c]+)\\u003c/a\\u003e', html):\\n results.append({\\\"title\\\": match.group(2).strip(), \\\"url\\\": match.group(1).strip()})\\n # Find snippets\\n snippets = re.findall(r'\\u003ca class=\\\"result__snippet\\\"[^\\u003e]*\\u003e(.*?)\\u003c/a\\u003e', html, re.DOTALL)\\n for i, snip in enumerate(snippets):\\n if i \\u003c len(results):\\n results[i][\\\"snippet\\\"] = re.sub(r'\\u003c[^\\u003e]+\\u003e', '', snip).strip()\\n \\n return results[:max_results]\\n\\n# Multiple searches in parallel\\nqueries = [\\n \\\"Escitalopram dose increase 5mg to 10mg long-term user effects\\\",\\n \\\"Escitalopram 5mg vs 10mg efficacy side effects study\\\",\\n \\\"Cipralex Dosiserhöhung 5mg auf 10mg Erfahrungen Nebenwirkungen\\\",\\n \\\"Escitalopram dose escalation long-term maintenance 5mg 10mg\\\",\\n \\\"SSRI dose increase after years stable low dose effects\\\",\\n \\\"Escitalopram 10mg side effects libido emotional blunting\\\",\\n]\\n\\nall_results = {}\\nfor q in queries:\\n try:\\n all_results[q] = duckduckgo_search(q, max_results=5)\\n except Exception as e:\\n all_results[q] = [{\\\"error\\\": str(e)}]\\n\\nprint(json.dumps(all_results, indent=2, ensure_ascii=False))\\n\"}" } } ] }, { "role": "tool", "name": "execute_code", "content": "{\"status\": \"success\", \"output\": \"{\\n \\\"Escitalopram dose increase 5mg to 10mg long-term user effects\\\": [],\\n \\\"Escitalopram 5mg vs 10mg efficacy side effects study\\\": [],\\n \\\"Cipralex Dosiserhöhung 5mg auf 10mg Erfahrungen Nebenwirkungen\\\": [],\\n \\\"Escitalopram dose escalation long-term maintenance 5mg 10mg\\\": [],\\n \\\"SSRI dose increase after years stable low dose effects\\\": [],\\n \\\"Escitalopram 10mg side effects libido emotional blunting\\\": []\\n}\\n\", \"tool_calls_made\": 0, \"duration_seconds\": 1.27}", "tool_call_id": "call_rqw5ubic" }, { "role": "assistant", "content": "DuckDuckGo HTML search returned empty. Let me try alternative search approaches.", "reasoning": "DuckDuckGo HTML search returned empty results. Let me try a different approach - maybe use web_search tool or try different search methods. Let me try using the web_search tool if available, or try curl-basedsearches.", "finish_reason": "tool_calls", "reasoning_content": "DuckDuckGo HTML search returned empty results. Let me try a different approach - maybe use web_search tool or try different search methods. Let me try using the web_search tool if available, or try curl-basedsearches.", "tool_calls": [ { "id": "call_iubsh9po", "call_id": "call_iubsh9po", "response_item_id": "fc_iubsh9po", "type": "function", "function": { "name": "execute_code", "arguments": "{\"code\":\"\\nimport json, urllib.request, urllib.parse, ssl\\n\\nctx = ssl.create_default_context()\\n\\n# Try Google search via startpage.com (privacy proxy)\\ndef startpage_search(query, max_results=8):\\n url = f\\\"https://www.startpage.com/sp/search?query={urllib.parse.quote(query)}\\u0026language=english\\\"\\n req = urllib.request.Request(url, headers={\\n \\\"User-Agent\\\": \\\"Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/120.0.0.0 Safari/537.36\\\"\\n })\\n with urllib.request.urlopen(req, context=ctx, timeout=15) as resp:\\n html = resp.read().decode(\\\"utf-8\\\", errors=\\\"replace\\\")\\n \\n import re\\n results = []\\n # Extract results from startpage\\n for match in re.finditer(r'\\u003ca[^\\u003e]*class=\\\"[^\\\"]*result-link[^\\\"]*\\\"[^\\u003e]*href=\\\"([^\\\"]+)\\\"[^\\u003e]*\\u003e([^\\u003c]+)\\u003c/a\\u003e', html):\\n results.append({\\\"title\\\": match.group(2).strip(), \\\"url\\\": match.group(1).strip()})\\n snippets = re.findall(r'\\u003cp[^\\u003e]*class=\\\"[^\\\"]*description[^\\\"]*\\\"[^\\u003e]*\\u003e(.*?)\\u003c/p\\u003e', html, re.DOTALL)\\n for i, snip in enumerate(snippets):\\n if i \\u003c len(results):\\n results[i][\\\"snippet\\\"] = re.sub(r'\\u003c[^\\u003e]+\\u003e', '', snip).strip()\\n \\n return results[:max_results]\\n\\n# Try multiple queries\\nqueries = [\\n \\\"escitalopram 5mg to 10mg dose increase long term\\\",\\n \\\"escitalopram 5mg vs 10mg efficacy side effects\\\",\\n \\\"Cipralex Dosiserhöhung 5mg 10mg Erfahrungen\\\",\\n \\\"escitalopram dose escalation maintenance\\\",\\n]\\n\\nall_results = {}\\nfor q in queries:\\n try:\\n all_results[q] = startpage_search(q, max_results=5)\\n except Exception as e:\\n all_results[q] = [{\\\"error\\\": str(e)}]\\n\\nprint(json.dumps(all_results, indent=2, ensure_ascii=False))\\n\"}" } } ] }, { "role": "tool", "name": "execute_code", "content": "{\"status\": \"success\", \"output\": \"{\\n \\\"escitalopram 5mg to 10mg dose increase long term\\\": [],\\n \\\"escitalopram 5mg vs 10mg efficacy side effects\\\": [],\\n \\\"Cipralex Dosiserhöhung 5mg 10mg Erfahrungen\\\": [],\\n \\\"escitalopram dose escalation maintenance\\\": []\\n}\\n\", \"tool_calls_made\": 0, \"duration_seconds\": 2.65}", "tool_call_id": "call_iubsh9po" }, { "role": "assistant", "content": "Web searches are returning empty. Let me try direct curl-based approaches.", "reasoning": "The web searches are returning empty results. Let me try a different approach - maybe using curl directly or trying other search engines. Let me try using the terminal with curl to access some search APIs or try different approaches.", "finish_reason": "tool_calls", "reasoning_content": "The web searches are returning empty results. Let me try a different approach - maybe using curl directly or trying other search engines. Let me try using the terminal with curl to access some search APIs or try different approaches.", "tool_calls": [ { "id": "call_d327gddw", "call_id": "call_d327gddw", "response_item_id": "fc_d327gddw", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://en.wikipedia.org/w/api.php?action=query\\u0026list=search\\u0026srsearch=escitalopram+dose+5mg+10mg\\u0026format=json\\u0026srlimit=5\\\" 2\\u003e\\u00261 | python3 -m json.tool 2\\u003e/dev/null | head -80\",\"timeout\":15}" } }, { "id": "call_s9hdyd5g", "call_id": "call_s9hdyd5g", "response_item_id": "fc_s9hdyd5g", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://api.duckduckgo.com/?q=escitalopram+5mg+10mg+dose+increase+side+effects\\u0026format=json\\u0026no_html=1\\u0026skip_disambig=1\\\" 2\\u003e\\u00261 | python3 -m json.tool 2\\u003e/dev/null | head -100\",\"timeout\":15}" } } ] }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"{\\n \\\"batchcomplete\\\": \\\"\\\",\\n \\\"query\\\": {\\n \\\"searchinfo\\\": {\\n \\\"totalhits\\\": 1,\\n \\\"suggestion\\\": \\\"escitalopram dove 5mg 1000\\\",\\n \\\"suggestionsnippet\\\": \\\"escitalopram dove 5mg 1000\\\"\\n },\\n \\\"search\\\": [\\n {\\n \\\"ns\\\": 0,\\n \\\"title\\\": \\\"Clobazam\\\",\\n \\\"pageid\\\": 2197412,\\n \\\"size\\\": 36649,\\n \\\"wordcount\\\": 3436,\\n \\\"snippet\\\": \\\"clobazam oral suspension 5mg/5ml and 10mg/5ml in France, Ireland, Germany, and Italy. Silocalm: clobazam oral suspension 5mg/5ml and 10mg/5ml in Denmark, Spain\\\",\\n \\\"timestamp\\\": \\\"2026-06-12T15:45:16Z\\\"\\n }\\n ]\\n }\\n}\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_d327gddw" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"{\\n \\\"Abstract\\\": \\\"\\\",\\n \\\"AbstractSource\\\": \\\"\\\",\\n \\\"AbstractText\\\": \\\"\\\",\\n \\\"AbstractURL\\\": \\\"\\\",\\n \\\"Answer\\\": \\\"\\\",\\n \\\"AnswerType\\\": \\\"\\\",\\n \\\"Definition\\\": \\\"\\\",\\n \\\"DefinitionSource\\\": \\\"\\\",\\n \\\"DefinitionURL\\\": \\\"\\\",\\n \\\"Entity\\\": \\\"\\\",\\n \\\"Heading\\\": \\\"\\\",\\n \\\"Image\\\": \\\"\\\",\\n \\\"ImageHeight\\\": \\\"\\\",\\n \\\"ImageIsLogo\\\": \\\"\\\",\\n \\\"ImageWidth\\\": \\\"\\\",\\n \\\"Infobox\\\": \\\"\\\",\\n \\\"Redirect\\\": \\\"\\\",\\n \\\"RelatedTopics\\\": [],\\n \\\"Results\\\": [],\\n \\\"Type\\\": \\\"\\\",\\n \\\"meta\\\": {\\n \\\"attribution\\\": null,\\n \\\"blockgroup\\\": null,\\n \\\"created_date\\\": \\\"2021-03-24\\\",\\n \\\"description\\\": \\\"testing\\\",\\n \\\"designer\\\": null,\\n \\\"dev_date\\\": \\\"2021-03-24\\\",\\n \\\"dev_milestone\\\": \\\"development\\\",\\n \\\"developer\\\": [\\n {\\n \\\"name\\\": \\\"zt\\\",\\n \\\"type\\\": \\\"duck.co\\\",\\n \\\"url\\\": \\\"https://duck.co/user/zt\\\"\\n }\\n ],\\n \\\"example_query\\\": \\\"\\\",\\n \\\"id\\\": \\\"just_another_test\\\",\\n \\\"is_stackexchange\\\": 0,\\n \\\"js_callback_name\\\": \\\"another_test\\\",\\n \\\"live_date\\\": null,\\n \\\"maintainer\\\": {\\n \\\"github\\\": \\\"\\\"\\n },\\n \\\"name\\\": \\\"Just Another Test\\\",\\n \\\"perl_module\\\": \\\"DDG::Lontail::AnotherTest\\\",\\n \\\"producer\\\": null,\\n \\\"production_state\\\": \\\"offline\\\",\\n \\\"repo\\\": \\\"fathead\\\",\\n \\\"signal_from\\\": \\\"just_another_test\\\",\\n \\\"src_domain\\\": \\\"how about there\\\",\\n \\\"src_id\\\": null,\\n \\\"src_name\\\": \\\"hi there\\\",\\n \\\"src_options\\\": {\\n \\\"directory\\\": \\\"\\\",\\n \\\"is_fanon\\\": 0,\\n \\\"is_mediawiki\\\": 0,\\n \\\"is_wikipedia\\\": 0,\\n \\\"language\\\": \\\"\\\",\\n \\\"min_abstract_length\\\": null,\\n \\\"skip_abstract\\\": 0,\\n \\\"skip_abstract_paren\\\": 0,\\n \\\"skip_icon\\\": 0,\\n \\\"skip_image_name\\\": 0,\\n \\\"skip_qr\\\": \\\"\\\",\\n \\\"src_info\\\": \\\"\\\",\\n \\\"src_skip\\\": \\\"\\\"\\n },\\n \\\"src_url\\\": \\\"Hello there\\\",\\n \\\"status\\\": null,\\n \\\"tab\\\": \\\"is this source\\\",\\n \\\"topic\\\": [],\\n \\\"unsafe\\\": null\\n }\\n}\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_s9hdyd5g" }, { "role": "assistant", "content": "Web search APIs are returning empty. Let me try direct medical sources and PubMed.", "reasoning": "The web search tools aren't returning useful results. Let me try a different approach - maybe I can use PubMed or other medical databases, or try Google Scholar. Let me also try direct curl to some known medical sites.", "finish_reason": "tool_calls", "reasoning_content": "The web search tools aren't returning useful results. Let me try a different approach - maybe I can use PubMed or other medical databases, or try Google Scholar. Let me also try direct curl to some known medical sites.", "tool_calls": [ { "id": "call_ani8xacc", "call_id": "call_ani8xacc", "response_item_id": "fc_ani8xacc", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=10\\u0026term=escitalopram+dose+increase+5mg+10mg+long+term\\\" 2\\u003e\\u00261 | head -100\",\"timeout\":15}" } }, { "id": "call_eet9o92i", "call_id": "call_eet9o92i", "response_item_id": "fc_eet9o92i", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=10\\u0026term=escitalopram+5mg+vs+10mg+efficacy+side+effects\\\" 2\\u003e\\u00261 | head -100\",\"timeout\":15}" } }, { "id": "call_2vsg50uw", "call_id": "call_2vsg50uw", "response_item_id": "fc_2vsg50uw", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=10\\u0026term=escitalopram+dose+escalation+maintenance+depression\\\" 2\\u003e\\u00261 | head -100\",\"timeout\":15}" } } ] }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n000 escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] increase \\\"increase\\\"[All Fields] OR \\\"increased\\\"[All Fields] OR \\\"increases\\\"[All Fields] OR \\\"increasing\\\"[All Fields] OR \\\"increasings\\\"[All Fields] term \\\"term birth\\\"[MeSH Terms] OR (\\\"term\\\"[All Fields] AND \\\"birth\\\"[All Fields]) OR \\\"term birth\\\"[All Fields] OR \\\"term\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND \\\"dose\\\"[All Fields] AND (\\\"increase\\\"[All Fields] OR \\\"increased\\\"[All Fields] OR \\\"increases\\\"[All Fields] OR \\\"increasing\\\"[All Fields] OR \\\"increasings\\\"[All Fields]) AND \\\"5mg\\\"[All Fields] AND \\\"10mg\\\"[All Fields] AND \\\"long\\\"[All Fields] AND (\\\"term birth\\\"[MeSH Terms] OR (\\\"term\\\"[All Fields] AND \\\"birth\\\"[All Fields]) OR \\\"term birth\\\"[All Fields] OR \\\"term\\\"[All Fields])No items found.\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_ani8xacc" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n000 escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] efficacy \\\"efficacies\\\"[All Fields] OR \\\"efficacious\\\"[All Fields] OR \\\"efficaciously\\\"[All Fields] OR \\\"efficaciousness\\\"[All Fields] OR \\\"efficacy\\\"[All Fields] side effects \\\"adverse effects\\\"[Subheading] OR (\\\"adverse\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"adverse effects\\\"[All Fields] OR (\\\"side\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"side effects\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND \\\"5mg\\\"[All Fields] AND \\\"vs\\\"[All Fields] AND \\\"10mg\\\"[All Fields] AND (\\\"efficacies\\\"[All Fields] OR \\\"efficacious\\\"[All Fields] OR \\\"efficaciously\\\"[All Fields] OR \\\"efficaciousness\\\"[All Fields] OR \\\"efficacy\\\"[All Fields]) AND (\\\"adverse effects\\\"[MeSH Subheading] OR (\\\"adverse\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"adverse effects\\\"[All Fields] OR (\\\"side\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"side effects\\\"[All Fields])No items found.\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_eet9o92i" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n110\\n38536761\\n escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] escalation \\\"escalate\\\"[All Fields] OR \\\"escalated\\\"[All Fields] OR \\\"escalates\\\"[All Fields] OR \\\"escalating\\\"[All Fields] OR \\\"escalation\\\"[All Fields] OR \\\"escalations\\\"[All Fields] maintenance \\\"maintenance\\\"[MeSH Terms] OR \\\"maintenance\\\"[All Fields] OR \\\"maintenances\\\"[All Fields] depression \\\"depressed\\\"[All Fields] OR \\\"depression\\\"[MeSH Terms] OR \\\"depression\\\"[All Fields] OR \\\"depressions\\\"[All Fields] OR \\\"depression's\\\"[All Fields] OR \\\"depressive disorder\\\"[MeSH Terms] OR (\\\"depressive\\\"[All Fields] AND \\\"disorder\\\"[All Fields]) OR \\\"depressive disorder\\\"[All Fields] OR \\\"depressivity\\\"[All Fields] OR \\\"depressive\\\"[All Fields] OR \\\"depressively\\\"[All Fields] OR \\\"depressiveness\\\"[All Fields] OR \\\"depressives\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND \\\"dose\\\"[All Fields] AND (\\\"escalate\\\"[All Fields] OR \\\"escalated\\\"[All Fields] OR \\\"escalates\\\"[All Fields] OR \\\"escalating\\\"[All Fields] OR \\\"escalation\\\"[All Fields] OR \\\"escalations\\\"[All Fields]) AND (\\\"maintenance\\\"[MeSH Terms] OR \\\"maintenance\\\"[All Fields] OR \\\"maintenances\\\"[All Fields]) AND (\\\"depressed\\\"[All Fields] OR \\\"depression\\\"[MeSH Terms] OR \\\"depression\\\"[All Fields] OR \\\"depressions\\\"[All Fields] OR \\\"depression s\\\"[All Fields] OR \\\"depressive disorder\\\"[MeSH Terms] OR (\\\"depressive\\\"[All Fields] AND \\\"disorder\\\"[All Fields]) OR \\\"depressive disorder\\\"[All Fields] OR \\\"depressivity\\\"[All Fields] OR \\\"depressive\\\"[All Fields] OR \\\"depressively\\\"[All Fields] OR \\\"depressiveness\\\"[All Fields] OR \\\"depressives\\\"[All Fields])\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_2vsg50uw" }, { "role": "assistant", "content": "Let me try broader PubMed searches and also access some direct medical sources.", "reasoning": "Let me try broader PubMed searches and also try to access some direct medical sources.", "finish_reason": "tool_calls", "reasoning_content": "Let me try broader PubMed searches and also try to access some direct medical sources.", "tool_calls": [ { "id": "call_zd7s3w69", "call_id": "call_zd7s3w69", "response_item_id": "fc_zd7s3w69", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=15\\u0026term=escitalopram+dose+response+depression+anxiety\\\" 2\\u003e\\u00261\",\"timeout\":15}" } }, { "id": "call_zqm53axr", "call_id": "call_zqm53axr", "response_item_id": "fc_zqm53axr", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=15\\u0026term=escitalopram+side+effects+sexual+dysfunction+emotional+blunting\\\" 2\\u003e\\u00261\",\"timeout\":15}" } }, { "id": "call_9gcuk6jc", "call_id": "call_9gcuk6jc", "response_item_id": "fc_9gcuk6jc", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=15\\u0026term=escitalopram+10mg+fixed+dose+trial\\\" 2\\u003e\\u00261\",\"timeout\":15}" } } ] }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n45150\\n40761981\\n40413068\\n37827257\\n37521489\\n37056809\\n36936596\\n35126139\\n34454055\\n32991792\\n30170329\\n30047820\\n28953649\\n25768383\\n24511235\\n23881184\\n escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] dose response \\\"Dose Response\\\"[Journal:__jid101308899] OR (\\\"dose\\\"[All Fields] AND \\\"response\\\"[All Fields]) OR \\\"dose response\\\"[All Fields] depression anxiety \\\"Depress Anxiety\\\"[Journal:__jid9708816] OR \\\"Arch Depress Anxiety\\\"[Journal:__jid101765132] OR (\\\"depression\\\"[All Fields] AND \\\"anxiety\\\"[All Fields]) OR \\\"depression anxiety\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND (\\\"dose response\\\"[Journal] OR (\\\"dose\\\"[All Fields] AND \\\"response\\\"[All Fields]) OR \\\"dose response\\\"[All Fields]) AND (\\\"depress anxiety\\\"[Journal] OR \\\"arch depress anxiety\\\"[Journal] OR (\\\"depression\\\"[All Fields] AND \\\"anxiety\\\"[All Fields]) OR \\\"depression anxiety\\\"[All Fields])\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_zd7s3w69" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n000 escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] side effects \\\"adverse effects\\\"[Subheading] OR (\\\"adverse\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"adverse effects\\\"[All Fields] OR (\\\"side\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"side effects\\\"[All Fields] sexual dysfunction \\\"sexual dysfunctions, psychological\\\"[MeSH Terms] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunctions\\\"[All Fields] AND \\\"psychological\\\"[All Fields]) OR \\\"psychological sexual dysfunctions\\\"[All Fields] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunction\\\"[All Fields]) OR \\\"sexual dysfunction\\\"[All Fields] OR \\\"sexual dysfunction, physiological\\\"[MeSH Terms] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunction\\\"[All Fields] AND \\\"physiological\\\"[All Fields]) OR \\\"physiological sexual dysfunction\\\"[All Fields] emotional \\\"emoting\\\"[All Fields] OR \\\"emotion's\\\"[All Fields] OR \\\"emotions\\\"[MeSH Terms] OR \\\"emotions\\\"[All Fields] OR \\\"emotion\\\"[All Fields] OR \\\"emotional\\\"[All Fields] OR \\\"emotive\\\"[All Fields] blunting \\\"blunt\\\"[All Fields] OR \\\"blunted\\\"[All Fields] OR \\\"blunting\\\"[All Fields] OR \\\"blunts\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND (\\\"adverse effects\\\"[MeSH Subheading] OR (\\\"adverse\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"adverse effects\\\"[All Fields] OR (\\\"side\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"side effects\\\"[All Fields]) AND (\\\"sexual dysfunctions, psychological\\\"[MeSH Terms] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunctions\\\"[All Fields] AND \\\"psychological\\\"[All Fields]) OR \\\"psychological sexual dysfunctions\\\"[All Fields] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunction\\\"[All Fields]) OR \\\"sexual dysfunction\\\"[All Fields] OR \\\"sexual dysfunction, physiological\\\"[MeSH Terms] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunction\\\"[All Fields] AND \\\"physiological\\\"[All Fields]) OR \\\"physiological sexual dysfunction\\\"[All Fields]) AND (\\\"emoting\\\"[All Fields] OR \\\"emotion s\\\"[All Fields] OR \\\"emotions\\\"[MeSH Terms] OR \\\"emotions\\\"[All Fields] OR \\\"emotion\\\"[All Fields] OR \\\"emotional\\\"[All Fields] OR \\\"emotive\\\"[All Fields]) AND (\\\"blunt\\\"[All Fields] OR \\\"blunted\\\"[All Fields] OR \\\"blunting\\\"[All Fields] OR \\\"blunts\\\"[All Fields])No items found.\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_zqm53axr" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n110\\n20452031\\n escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] fixed \\\"fixatives\\\"[Pharmacological Action] OR \\\"fixatives\\\"[Supplementary Concept] OR \\\"fixatives\\\"[All Fields] OR \\\"fixative\\\"[All Fields] OR \\\"fixatives\\\"[MeSH Terms] OR \\\"fixed\\\"[All Fields] OR \\\"fixes\\\"[All Fields] OR \\\"fixing\\\"[All Fields] OR \\\"fixings\\\"[All Fields] trial \\\"clinical trials as topic\\\"[MeSH Terms] OR (\\\"clinical\\\"[All Fields] AND \\\"trials\\\"[All Fields] AND \\\"topic\\\"[All Fields]) OR \\\"clinical trials as topic\\\"[All Fields] OR \\\"trial\\\"[All Fields] OR \\\"trial's\\\"[All Fields] OR \\\"trialed\\\"[All Fields] OR \\\"trialing\\\"[All Fields] OR \\\"trials\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND \\\"10mg\\\"[All Fields] AND (\\\"fixatives\\\"[Pharmacological Action] OR \\\"fixatives\\\"[Supplementary Concept] OR \\\"fixatives\\\"[All Fields] OR \\\"fixative\\\"[All Fields] OR \\\"fixatives\\\"[MeSH Terms] OR \\\"fixed\\\"[All Fields] OR \\\"fixes\\\"[All Fields] OR \\\"fixing\\\"[All Fields] OR \\\"fixings\\\"[All Fields]) AND \\\"dose\\\"[All Fields] AND (\\\"clinical trials as topic\\\"[MeSH Terms] OR (\\\"clinical\\\"[All Fields] AND \\\"trials\\\"[All Fields] AND \\\"topic\\\"[All Fields]) OR \\\"clinical trials as topic\\\"[All Fields] OR \\\"trial\\\"[All Fields] OR \\\"trial s\\\"[All Fields] OR \\\"trialed\\\"[All Fields] OR \\\"trialing\\\"[All Fields] OR \\\"trials\\\"[All Fields])\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_9gcuk6jc" }, { "role": "assistant", "content": "Got some PubMed IDs. Let me fetch the abstracts of the most relevant papers.", "reasoning": "The PubMed searches are returning some results. Let me now fetch the abstracts of the most relevant papers. I have 45 results for dose-response, and a few specific ones. Let me fetch the key ones.", "finish_reason": "tool_calls", "reasoning_content": "The PubMed searches are returning some results. Let me now fetch the abstracts of the most relevant papers. I have 45 results for dose-response, and a few specific ones. Let me fetch the key ones.", "tool_calls": [ { "id": "call_d8xn2u9v", "call_id": "call_d8xn2u9v", "response_item_id": "fc_d8xn2u9v", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed\\u0026id=40761981,40413068,37827257,37521489,37056809,36936596,35126139,34454055,32991792,30170329,30047820,28953649,25768383,24511235,23881184\\u0026rettype=abstract\\u0026retmode=xml\\\" 2\\u003e\\u00261 | python3 -c \\\"\\nimport sys, xml.etree.ElementTree as ET\\ntree = ET.parse(sys.stdin)\\nroot = tree.getroot()\\nfor article in root.findall('.//PubmedArticle'):\\n pmid = article.find('.//PMID').text\\n title = article.find('.//ArticleTitle')\\n title_text = title.text if title is not None else 'N/A'\\n abstract = article.find('.//AbstractText')\\n abstract_text = abstract.text if abstract is not None else 'N/A'\\n journal = article.find('.//Journal/Title')\\n journal_text = journal.text if journal is not None else 'N/A'\\n year = article.find('.//PubDate/Year')\\n year_text = year.text if year is not None else 'N/A'\\n print(f'=== PMID: {pmid} | {journal_text} ({year_text}) ===')\\n print(f'Title: {title_text}')\\n print(f'Abstract: {abstract_text[:500]}')\\n print()\\n\\\" 2\\u003e\\u00261 | head -200\",\"timeout\":20}" } }, { "id": "call_2rpbf9uy", "call_id": "call_2rpbf9uy", "response_item_id": "fc_2rpbf9uy", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed\\u0026id=20452031,38536761\\u0026rettype=abstract\\u0026retmode=xml\\\" 2\\u003e\\u00261 | python3 -c \\\"\\nimport sys, xml.etree.ElementTree as ET\\ntree = ET.parse(sys.stdin)\\nroot = tree.getroot()\\nfor article in root.findall('.//PubmedArticle'):\\n pmid = article.find('.//PMID').text\\n title = article.find('.//ArticleTitle')\\n title_text = title.text if title is not None else 'N/A'\\n abstract = article.find('.//AbstractText')\\n abstract_text = abstract.text if abstract is not None else 'N/A'\\n journal = article.find('.//Journal/Title')\\n journal_text = journal.text if journal is not None else 'N/A'\\n year = article.find('.//PubDate/Year')\\n year_text = year.text if year is not None else 'N/A'\\n print(f'=== PMID: {pmid} | {journal_text} ({year_text}) ===')\\n print(f'Title: {title_text}')\\n print(f'Abstract: {abstract_text[:800]}')\\n print()\\n\\\" 2\\u003e\\u00261\",\"timeout\":20}" } } ] }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"=== PMID: 40761981 | Cureus (2025) ===\\nTitle: Symptom Reduction and Deprescribing in a Patient With Treatment-Resistant Depression Using Sublingual Ketamine Troches: A Case Report.\\nAbstract: Treatment-resistant depression (TRD) remains a significant clinical challenge, often accompanied by polypharmacy and comorbid anxiety or trauma-related disorders. This report describes a 37-year-old male with longstanding major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and social anxiety disorder who demonstrated limited response to traditional pharmacologic strategies, including escitalopram, quetiapine, trazodone, and gabapentin. After initiating low-dose sublingual ket\\n\\n=== PMID: 40413068 | L'Encephale (2025) ===\\nTitle: [Psilocybin in the setting of treatment-resistant unipolar depression: A case report].\\nAbstract: Current antidepressants have shown certain limitations in the treatment of unipolar depression. Their long onset of action, interactions, and side effects are obstacles to achieving lasting remission of this prevalent, often chronic or recurrent, pathology. Faced with this clinical necessity, research efforts have intensified in recent years around psychedelic drugs, with a particular focus on the mental health benefits of psilocybin. To illustrate this promising approach, we present here the cl\\n\\n=== PMID: 37827257 | Journal of affective disorders (2024) ===\\nTitle: Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.\\nAbstract: To explore the effect of escitalopram combined with aripiprazole on cognitive function in patients with major depressive disorder (MDD), and to evaluate the clinical efficacy of the combination therapy.\\n\\n=== PMID: 37521489 | Journal of experimental pharmacology (2023) ===\\nTitle: Efficacy and Anti-Inflammatory Activity of Ashwagandha Sustained-Release Formulation on Depression and Anxiety Induced by Chronic Unpredictable Stress: in vivo and in vitro Studies.\\nAbstract: Stress is the psychological, physiological, and behavioral response of an individual's body when they perceive a lack of equilibrium between the demands placed upon them and their ability to meet those demands. Adaptogens are herbs that help with stress management, and Ashwagandha is one such safe and effective adaptogen.\\n\\n=== PMID: 37056809 | American journal of translational research (2023) ===\\nTitle: Effects of escitalopram oxalate plus low-dose trazodone on psychological state and quality of life in patients with treatment-refractory depression.\\nAbstract: To analyze the effect of escitalopram oxalate (ESC) plus low-dose (LD) trazodone (TRA) on the psychological state and quality of life (QOL) of patients with treatment-refractory depression (TRD).\\n\\n=== PMID: 36936596 | BMJ medicine (2022) ===\\nTitle: Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis.\\nAbstract: To assess and clarify the relations between selective serotonin reuptake inhibitor (SSRI) dose efficacy, acceptability (early treatment discontinuation (dropouts)), and tolerability (reported adverse drug effects), and critically evaluate methods previously used to examine SSRI dose-response effects for the treatment of depression in adults.\\n\\n=== PMID: 35126139 | Frontiers in pharmacology (2021) ===\\nTitle: Spontaneous Activity of CB\\nAbstract: The monoaminergic theory of depression/anxiety disorders cannot fully explain the behavioral and neuroplastic changes observed after ADs chronic treatment. Endocannabinoid system, which comprises CB2 receptors, has been associated with the chronic effects of these drugs, especially in stressed mice. CB2-KO mice display more vulnerability to stressful stimuli. In the present study, we hypothesized that the behavioral and neuroplastic effects observed after repeated treatment with the AD escitalop\\n\\n=== PMID: 34454055 | Journal of ethnopharmacology (2022) ===\\nTitle: An acute dose-ranging evaluation of the antidepressant properties of Sceletium tortuosum (Zembrin®) versus escitalopram in the Flinders Sensitive Line rat.\\nAbstract: Sceletium tortuosum (L.) N.E.Br. (ST) has been used by the Khoisan people of South Africa as a mood elevator. Its various pharmacological mechanisms of action suggest distinct potential as an antidepressant. Clinical studies in healthy individuals suggest beneficial effects on mood, cognition, and anxiety.\\n\\n=== PMID: 32991792 | The Journal of clinical psychiatry (2020) ===\\nTitle: Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.\\nAbstract: There is a paucity of data on the effects of coprescribed benzodiazepines on treatment response variability and adherence to antidepressant pharmacotherapy for depression and anxiety in late life. The objective of this transdiagnostic analysis was to examine the effect of benzodiazepines on treatment outcomes in older patients with generalized anxiety disorder (GAD) or major depressive disorder (MDD).\\n\\n=== PMID: 30170329 | Pharmacopsychiatry (2019) ===\\nTitle: Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study.\\nAbstract: This study tests the efficacy of pregabalin versus placebo as adjunctive treatment in patients with generalized anxiety disorder (GAD) comorbid with unipolar major depression (UMD) and with an early nonresponse to escitalopram.\\n\\n=== PMID: 30047820 | Journal of psychopharmacology (Oxford, England) (2018) ===\\nTitle: Efficacy of vortioxetine on the physical symptoms of major depressive disorder.\\nAbstract: Efficacy has been proven for vortioxetine in short-term and long-term treatment of major depressive disorder (MDD), with broad beneficial effects on emotional, physical and cognitive symptoms. Limited specific data on the effects of vortioxetine on depression-related physical symptoms have been published.\\n\\n=== PMID: 28953649 | Medicine (2017) ===\\nTitle: Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: A pooled analysis of 4 Chinese clinical trials.\\nAbstract: This study aimed to evaluate the efficacy of escitalopram monotherapy in the treatment of major depressive disorder (MDD) on the basis of pooled data analysis of 4 Chinese clinical trials.A total of 649 outpatients with MDD score of ≥18 at the 17-item Hamilton Depression Rating Scale (HAMD17) were included across 4 eligible studies. Patients were treated with 10 mg/day escitalopram for 2 weeks, and then 20 mg/day escitalopram was administered if the clinical response was poor.The change in total\\n\\n=== PMID: 25768383 | International clinical psychopharmacology (2015) ===\\nTitle: Treating mood disorders in patients with a history of intestinal surgery: a systematic review.\\nAbstract: Bariatric surgery is increasingly being performed, with the intended benefits of significant and durable weight loss. Radical surgical resection can result in short bowel syndrome (SBS), a rare and devastating condition. Psychological distress is common in these patients. Relevant articles were identified by searching Pubmed and EMBASE databases with the following keywords: 'Bariatrics'[Mesh] OR 'Short Bowel Syndrome' AND 'Antidepressive Agents' OR 'Psychotropic Drugs'[Mesh]. One in-vitro study,\\n\\n=== PMID: 24511235 | Neuropsychiatric disease and treatment (2014) ===\\nTitle: A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder.\\nAbstract: To evaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD).\\n\\n=== PMID: 23881184 | International clinical psychopharmacology (2013) ===\\nTitle: Comparison of escitalopram and paroxetine in the treatment of major depressive disorder.\\nAbstract: This is a single-blind, parallel, flexible-dose study to compare the efficacy and tolerability of escitalopram and paroxetine in the treatment of patients with major depressive disorder. We recruited 399 patients from the outpatient clinics of five hospitals in northern Taiwan. Patients were administered either escitalopram (10-30 mg) or paroxetine (20-40 mg) according to the judgment of clinicians. These patients were assessed using the Hamilton Rating Scale for Depression (HAM-D) and the Hamil\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_d8xn2u9v" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"=== PMID: 20452031 | Journal of affective disorders (2010) ===\\nTitle: MRI signal hyperintensities and treatment remission of geriatric depression.\\nAbstract: White matter abnormalities may interfere with limbic-cortical balance and contribute to chronic depressive syndromes in the elderly. This study sought to clarify the relationship of SH to treatment response. We hypothesized that patients who failed to remit during a 12-week controlled treatment trial of escitalopram would exhibit greater SH burden than patients who remitted.\\n\\n=== PMID: 38536761 | Expert review of neurotherapeutics (2024) ===\\nTitle: Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder.\\nAbstract: Major Depressive Disorder (MDD) is a mental health issue that significantly affects patients' quality of life and functioning. Despite available treatments, many patients continue to suffer due to incomplete symptom resolution and side effects.\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_2rpbf9uy" }, { "role": "assistant", "content": "Let me get the full abstract of the most relevant paper (the dose-response systematic review) and try more targeted searches.", "reasoning": "The PubMed results are mostly about treatment-resistant depression, augmentation strategies, and other topics — not directly about escitalopram dose increase from 5mg to 10mg. Let me try more targeted searches and also look at the key paper PMID 36936596 which is a systematic review of SSRI dose-response effects. Let me also try to access some German-language resources and the official prescribing information.", "finish_reason": "tool_calls", "reasoning_content": "The PubMed results are mostly about treatment-resistant depression, augmentation strategies, and other topics — not directly about escitalopram dose increase from 5mg to 10mg. Let me try more targeted searches and also look at the key paper PMID 36936596 which is a systematic review of SSRI dose-response effects. Let me also try to access some German-language resources and the official prescribing information.", "tool_calls": [ { "id": "call_1exe7yue", "call_id": "call_1exe7yue", "response_item_id": "fc_1exe7yue", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed\\u0026id=36936596\\u0026rettype=abstract\\u0026retmode=xml\\\" 2\\u003e\\u00261 | python3 -c \\\"\\nimport sys, xml.etree.ElementTree as ET\\ntree = ET.parse(sys.stdin)\\nroot = tree.getroot()\\nfor article in root.findall('.//PubmedArticle'):\\n pmid = article.find('.//PMID').text\\n title = article.find('.//ArticleTitle').text\\n # Get all abstract parts\\n abstract_parts = article.findall('.//AbstractText')\\n full_abstract = ' '.join([a.text or '' for a in abstract_parts])\\n journal = article.find('.//Journal/Title').text\\n year = article.find('.//PubDate/Year').text\\n print(f'=== PMID: {pmid} | {journal} ({year}) ===')\\n print(f'Title: {title}')\\n print(f'Abstract: {full_abstract}')\\n\\\" 2\\u003e\\u00261\",\"timeout\":20}" } }, { "id": "call_vjwaerox", "call_id": "call_vjwaerox", "response_item_id": "fc_vjwaerox", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=10\\u0026term=escitalopram+10mg+standard+dose+depression+randomized\\\" 2\\u003e\\u00261\",\"timeout\":15}" } }, { "id": "call_6cfzdh4i", "call_id": "call_6cfzdh4i", "response_item_id": "fc_6cfzdh4i", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=10\\u0026term=SSRI+dose+increase+long+term+maintenance+side+effects\\\" 2\\u003e\\u00261\",\"timeout\":15}" } } ] }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"=== PMID: 36936596 | BMJ medicine (2022) ===\\nTitle: Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis.\\nAbstract: To assess and clarify the relations between selective serotonin reuptake inhibitor (SSRI) dose efficacy, acceptability (early treatment discontinuation (dropouts)), and tolerability (reported adverse drug effects), and critically evaluate methods previously used to examine SSRI dose-response effects for the treatment of depression in adults. Systematic review of reviews and meta-narrative synthesis. Embase, Medline, PsycINFO, Scopus, and the Cochrane Collaboration library, from 1975 to December 2021. Reference lists of national depression treatment guidelines were systemically searched by hand. Reviews assessing SSRI monotherapy dose-response effects for the treatment of depression in adults (age ≥18 years) reporting efficacy, acceptability, or tolerability. Reviews meeting inclusion criteria had a high degree of heterogeneity, due to methodological diversity; therefore, a meta-narrative synthesis approach was applied. Standard daily doses were defined as 20 mg citalopram, fluoxetine, paroxetine; 50 mg sertraline; and 10 mg escitalopram. Risk of bias was assessed using the Risk of Bias in Systematic Reviews tool, in line with Cochrane recommendations. The search identified 9138 records; 387 full text reports were assessed for eligibility, 42 of which matched the inclusion criteria. The majority, 83% (n=35), of reviews included data for studies with a duration of ≤12 weeks (ie, the acute phase of depression treatment). Of 39 reviews assessing efficacy, the majority (n=26) indicated that individual SSRIs and SSRI class demonstrated flat dose-response effects; standard doses were optimal for efficacy. Acceptability or tolerability were assessed in 28 reviews. Higher than standard daily doses were associated with higher dropout rates and a greater incidence of adverse drug effects (eg, nausea, sexual dysfunction, fatigue, anxiety). Despite a range of methods being reported, there was an overall consensus regarding SSRI dose related efficacy, dropouts, and adverse drug effects. Standard daily doses of SSRIs for the treatment of depression in adults provide a favourable balance between efficacy, acceptability, and tolerability. Patients are encouraged to talk to their prescriber or community pharmacist if they experience adverse effects or have any concerns about their drug treatments.\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_1exe7yue" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n000 escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] standard \\\"reference standards\\\"[MeSH Terms] OR (\\\"reference\\\"[All Fields] AND \\\"standards\\\"[All Fields]) OR \\\"reference standards\\\"[All Fields] OR \\\"standardization\\\"[All Fields] OR \\\"standard\\\"[All Fields] OR \\\"standard's\\\"[All Fields] OR \\\"standardisation\\\"[All Fields] OR \\\"standardisations\\\"[All Fields] OR \\\"standardise\\\"[All Fields] OR \\\"standardised\\\"[All Fields] OR \\\"standardises\\\"[All Fields] OR \\\"standardising\\\"[All Fields] OR \\\"standardization's\\\"[All Fields] OR \\\"standardizations\\\"[All Fields] OR \\\"standardize\\\"[All Fields] OR \\\"standardized\\\"[All Fields] OR \\\"standardizes\\\"[All Fields] OR \\\"standardizing\\\"[All Fields] OR \\\"standards\\\"[Subheading] OR \\\"standards\\\"[All Fields] depression \\\"depressed\\\"[All Fields] OR \\\"depression\\\"[MeSH Terms] OR \\\"depression\\\"[All Fields] OR \\\"depressions\\\"[All Fields] OR \\\"depression's\\\"[All Fields] OR \\\"depressive disorder\\\"[MeSH Terms] OR (\\\"depressive\\\"[All Fields] AND \\\"disorder\\\"[All Fields]) OR \\\"depressive disorder\\\"[All Fields] OR \\\"depressivity\\\"[All Fields] OR \\\"depressive\\\"[All Fields] OR \\\"depressively\\\"[All Fields] OR \\\"depressiveness\\\"[All Fields] OR \\\"depressives\\\"[All Fields] randomized \\\"random allocation\\\"[MeSH Terms] OR (\\\"random\\\"[All Fields] AND \\\"allocation\\\"[All Fields]) OR \\\"random allocation\\\"[All Fields] OR \\\"randomization\\\"[All Fields] OR \\\"randomized\\\"[All Fields] OR \\\"random\\\"[All Fields] OR \\\"randomisation\\\"[All Fields] OR \\\"randomisations\\\"[All Fields] OR \\\"randomise\\\"[All Fields] OR \\\"randomised\\\"[All Fields] OR \\\"randomising\\\"[All Fields] OR \\\"randomizations\\\"[All Fields] OR \\\"randomize\\\"[All Fields] OR \\\"randomizes\\\"[All Fields] OR \\\"randomizing\\\"[All Fields] OR \\\"randomness\\\"[All Fields] OR \\\"randoms\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND \\\"10mg\\\"[All Fields] AND (\\\"reference standards\\\"[MeSH Terms] OR (\\\"reference\\\"[All Fields] AND \\\"standards\\\"[All Fields]) OR \\\"reference standards\\\"[All Fields] OR \\\"standardization\\\"[All Fields] OR \\\"standard\\\"[All Fields] OR \\\"standard s\\\"[All Fields] OR \\\"standardisation\\\"[All Fields] OR \\\"standardisations\\\"[All Fields] OR \\\"standardise\\\"[All Fields] OR \\\"standardised\\\"[All Fields] OR \\\"standardises\\\"[All Fields] OR \\\"standardising\\\"[All Fields] OR \\\"standardization s\\\"[All Fields] OR \\\"standardizations\\\"[All Fields] OR \\\"standardize\\\"[All Fields] OR \\\"standardized\\\"[All Fields] OR \\\"standardizes\\\"[All Fields] OR \\\"standardizing\\\"[All Fields] OR \\\"standards\\\"[MeSH Subheading] OR \\\"standards\\\"[All Fields]) AND \\\"dose\\\"[All Fields] AND (\\\"depressed\\\"[All Fields] OR \\\"depression\\\"[MeSH Terms] OR \\\"depression\\\"[All Fields] OR \\\"depressions\\\"[All Fields] OR \\\"depression s\\\"[All Fields] OR \\\"depressive disorder\\\"[MeSH Terms] OR (\\\"depressive\\\"[All Fields] AND \\\"disorder\\\"[All Fields]) OR \\\"depressive disorder\\\"[All Fields] OR \\\"depressivity\\\"[All Fields] OR \\\"depressive\\\"[All Fields] OR \\\"depressively\\\"[All Fields] OR \\\"depressiveness\\\"[All Fields] OR \\\"depressives\\\"[All Fields]) AND (\\\"random allocation\\\"[MeSH Terms] OR (\\\"random\\\"[All Fields] AND \\\"allocation\\\"[All Fields]) OR \\\"random allocation\\\"[All Fields] OR \\\"randomization\\\"[All Fields] OR \\\"randomized\\\"[All Fields] OR \\\"random\\\"[All Fields] OR \\\"randomisation\\\"[All Fields] OR \\\"randomisations\\\"[All Fields] OR \\\"randomise\\\"[All Fields] OR \\\"randomised\\\"[All Fields] OR \\\"randomising\\\"[All Fields] OR \\\"randomizations\\\"[All Fields] OR \\\"randomize\\\"[All Fields] OR \\\"randomizes\\\"[All Fields] OR \\\"randomizing\\\"[All Fields] OR \\\"randomness\\\"[All Fields] OR \\\"randoms\\\"[All Fields])No items found.\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_vjwaerox" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n550\\n38643950\\n32656861\\n20806989\\n9221240\\n1431019\\n increase \\\"increase\\\"[All Fields] OR \\\"increased\\\"[All Fields] OR \\\"increases\\\"[All Fields] OR \\\"increasing\\\"[All Fields] OR \\\"increasings\\\"[All Fields] term \\\"term birth\\\"[MeSH Terms] OR (\\\"term\\\"[All Fields] AND \\\"birth\\\"[All Fields]) OR \\\"term birth\\\"[All Fields] OR \\\"term\\\"[All Fields] maintenance \\\"maintenance\\\"[MeSH Terms] OR \\\"maintenance\\\"[All Fields] OR \\\"maintenances\\\"[All Fields] side effects \\\"adverse effects\\\"[Subheading] OR (\\\"adverse\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"adverse effects\\\"[All Fields] OR (\\\"side\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"side effects\\\"[All Fields] \\\"SSRI\\\"[All Fields] AND \\\"dose\\\"[All Fields] AND (\\\"increase\\\"[All Fields] OR \\\"increased\\\"[All Fields] OR \\\"increases\\\"[All Fields] OR \\\"increasing\\\"[All Fields] OR \\\"increasings\\\"[All Fields]) AND \\\"long\\\"[All Fields] AND (\\\"term birth\\\"[MeSH Terms] OR (\\\"term\\\"[All Fields] AND \\\"birth\\\"[All Fields]) OR \\\"term birth\\\"[All Fields] OR \\\"term\\\"[All Fields]) AND (\\\"maintenance\\\"[MeSH Terms] OR \\\"maintenance\\\"[All Fields] OR \\\"maintenances\\\"[All Fields]) AND (\\\"adverse effects\\\"[MeSH Subheading] OR (\\\"adverse\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"adverse effects\\\"[All Fields] OR (\\\"side\\\"[All Fields] AND \\\"effects\\\"[All Fields]) OR \\\"side effects\\\"[All Fields])\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_6cfzdh4i" }, { "role": "assistant", "content": "", "reasoning": "Let me fetch the remaining relevant abstracts and also try to access some German-language resources and clinical guidelines.", "finish_reason": "tool_calls", "reasoning_content": "Let me fetch the remaining relevant abstracts and also try to access some German-language resources and clinical guidelines.", "tool_calls": [ { "id": "call_8dv19oe5", "call_id": "call_8dv19oe5", "response_item_id": "fc_8dv19oe5", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed\\u0026id=38643950,32656861,20806989,28953649\\u0026rettype=abstract\\u0026retmode=xml\\\" 2\\u003e\\u00261 | python3 -c \\\"\\nimport sys, xml.etree.ElementTree as ET\\ntree = ET.parse(sys.stdin)\\nroot = tree.getroot()\\nfor article in root.findall('.//PubmedArticle'):\\n pmid = article.find('.//PMID').text\\n title = article.find('.//ArticleTitle').text\\n abstract_parts = article.findall('.//AbstractText')\\n full_abstract = ' '.join([a.text or '' for a in abstract_parts])\\n journal = article.find('.//Journal/Title').text\\n year = article.find('.//PubDate/Year').text\\n print(f'=== PMID: {pmid} | {journal} ({year}) ===')\\n print(f'Title: {title}')\\n print(f'Abstract: {full_abstract[:600]}')\\n print()\\n\\\" 2\\u003e\\u00261\",\"timeout\":20}" } }, { "id": "call_eukdrp6q", "call_id": "call_eukdrp6q", "response_item_id": "fc_eukdrp6q", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=10\\u0026term=escitalopram+sexual+dysfunction+prevalence+dose\\\" 2\\u003e\\u00261\",\"timeout\":15}" } }, { "id": "call_mm4gj44x", "call_id": "call_mm4gj44x", "response_item_id": "fc_mm4gj44x", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=10\\u0026term=escitalopram+emotional+blunting+apathy+SSRI\\\" 2\\u003e\\u00261\",\"timeout\":15}" } } ] }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"=== PMID: 38643950 | Toxicology and applied pharmacology (2024) ===\\nTitle: Dysregulation of adipogenesis and disrupted lipid metabolism by the antidepressants citalopram and sertraline.\\nAbstract: Selective Serotonin Reuptake Inhibitors (SSRIs) are widely used medications for the treatment of major depressive disorder. However, long-term SSRI use has been associated with weight gain and altered lipid profiles. These findings suggest that SSRIs may have negative effects on metabolism. Exposure to certain chemicals called 'obesogens' is known to promote lipid accumulation and obesity by modulating adipogenesis. Here, we investigated whether citalopram (CIT) and sertraline (SER) interfere with the process of adipogenesis, using human mesenchymal stem cells (MSCs) in a 2D and a 3D model. As\\n\\n=== PMID: 32656861 | British journal of clinical pharmacology (2021) ===\\nTitle: Strategies to reduce use of antidepressants.\\nAbstract: Antidepressant prescribing has increased year on year since the introduction of the selective serotonin reuptake inhibitors (SSRIs) in the 1980s. More than 10% of adults in England are now taking antidepressants for depression/anxiety, with a median length of treatment of more than 2 years, but antidepressants can cause side effects and withdrawal symptoms which increase with longer use. Surveys of antidepressant users suggest 30-50% have no evidence-based indication to continue, but coming off antidepressants is often difficult due to fears of relapse, withdrawal symptoms and a lack of psycho\\n\\n=== PMID: 20806989 | CNS drugs (2010) ===\\nTitle: Escitalopram: a review of its use in the management of major depressive disorder in adults.\\nAbstract: Escitalopram (escitalopram oxalate; Cipralex, Lexapro), a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD), demonstrates a highly selective and potent, dose-dependent inhibition of the human serotonin transporter, inhibiting serotonin reuptake into presynaptic nerve terminals and thus increasing serotonergic activity in the CNS. With regard to primary endpoints (such as improved scores on the Montgomery-Asberg Depression Rating Scale [MADRS] and the Hamilton Depression Rating Scale [HAM-D]), escitalopram was generally more effective t\\n\\n=== PMID: 28953649 | Medicine (2017) ===\\nTitle: Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: A pooled analysis of 4 Chinese clinical trials.\\nAbstract: This study aimed to evaluate the efficacy of escitalopram monotherapy in the treatment of major depressive disorder (MDD) on the basis of pooled data analysis of 4 Chinese clinical trials.A total of 649 outpatients with MDD score of ≥18 at the 17-item Hamilton Depression Rating Scale (HAMD17) were included across 4 eligible studies. Patients were treated with 10 mg/day escitalopram for 2 weeks, and then 20 mg/day escitalopram was administered if the clinical response was poor.The change in total HAMD17 score was significantly greater in moderate MDD group than in other subgroups (P < .001), bu\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_8dv19oe5" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n880\\n31977667\\n29588433\\n29034101\\n23094470\\n22122658\\n21477024\\n17627739\\n16528138\\n escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] sexual dysfunction \\\"sexual dysfunctions, psychological\\\"[MeSH Terms] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunctions\\\"[All Fields] AND \\\"psychological\\\"[All Fields]) OR \\\"psychological sexual dysfunctions\\\"[All Fields] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunction\\\"[All Fields]) OR \\\"sexual dysfunction\\\"[All Fields] OR \\\"sexual dysfunction, physiological\\\"[MeSH Terms] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunction\\\"[All Fields] AND \\\"physiological\\\"[All Fields]) OR \\\"physiological sexual dysfunction\\\"[All Fields] prevalence \\\"epidemiology\\\"[Subheading] OR \\\"epidemiology\\\"[All Fields] OR \\\"prevalence\\\"[All Fields] OR \\\"prevalence\\\"[MeSH Terms] OR \\\"prevalance\\\"[All Fields] OR \\\"prevalences\\\"[All Fields] OR \\\"prevalence's\\\"[All Fields] OR \\\"prevalent\\\"[All Fields] OR \\\"prevalently\\\"[All Fields] OR \\\"prevalents\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND (\\\"sexual dysfunctions, psychological\\\"[MeSH Terms] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunctions\\\"[All Fields] AND \\\"psychological\\\"[All Fields]) OR \\\"psychological sexual dysfunctions\\\"[All Fields] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunction\\\"[All Fields]) OR \\\"sexual dysfunction\\\"[All Fields] OR \\\"sexual dysfunction, physiological\\\"[MeSH Terms] OR (\\\"sexual\\\"[All Fields] AND \\\"dysfunction\\\"[All Fields] AND \\\"physiological\\\"[All Fields]) OR \\\"physiological sexual dysfunction\\\"[All Fields]) AND (\\\"epidemiology\\\"[MeSH Subheading] OR \\\"epidemiology\\\"[All Fields] OR \\\"prevalence\\\"[All Fields] OR \\\"prevalence\\\"[MeSH Terms] OR \\\"prevalance\\\"[All Fields] OR \\\"prevalences\\\"[All Fields] OR \\\"prevalence s\\\"[All Fields] OR \\\"prevalent\\\"[All Fields] OR \\\"prevalently\\\"[All Fields] OR \\\"prevalents\\\"[All Fields]) AND \\\"dose\\\"[All Fields]\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_eukdrp6q" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n000 escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] emotional \\\"emoting\\\"[All Fields] OR \\\"emotion's\\\"[All Fields] OR \\\"emotions\\\"[MeSH Terms] OR \\\"emotions\\\"[All Fields] OR \\\"emotion\\\"[All Fields] OR \\\"emotional\\\"[All Fields] OR \\\"emotive\\\"[All Fields] blunting \\\"blunt\\\"[All Fields] OR \\\"blunted\\\"[All Fields] OR \\\"blunting\\\"[All Fields] OR \\\"blunts\\\"[All Fields] apathy \\\"apathy\\\"[MeSH Terms] OR \\\"apathy\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND (\\\"emoting\\\"[All Fields] OR \\\"emotion s\\\"[All Fields] OR \\\"emotions\\\"[MeSH Terms] OR \\\"emotions\\\"[All Fields] OR \\\"emotion\\\"[All Fields] OR \\\"emotional\\\"[All Fields] OR \\\"emotive\\\"[All Fields]) AND (\\\"blunt\\\"[All Fields] OR \\\"blunted\\\"[All Fields] OR \\\"blunting\\\"[All Fields] OR \\\"blunts\\\"[All Fields]) AND (\\\"apathy\\\"[MeSH Terms] OR \\\"apathy\\\"[All Fields]) AND \\\"SSRI\\\"[All Fields]No items found.\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_mm4gj44x" }, { "role": "assistant", "content": "", "reasoning": "Let me now fetch the sexual dysfunction papers and the key escitalopram review paper, plus try to get the full abstract of the 2017 Chinese pooled analysis and the 2010 CNS Drugs review.", "finish_reason": "tool_calls", "reasoning_content": "Let me now fetch the sexual dysfunction papers and the key escitalopram review paper, plus try to get the full abstract of the 2017 Chinese pooled analysis and the 2010 CNS Drugs review.", "tool_calls": [ { "id": "call_negv2oul", "call_id": "call_negv2oul", "response_item_id": "fc_negv2oul", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed\\u0026id=31977667,29588433,29034101,23094470,22122658,21477024,17627739,16528138\\u0026rettype=abstract\\u0026retmode=xml\\\" 2\\u003e\\u00261 | python3 -c \\\"\\nimport sys, xml.etree.ElementTree as ET\\ntree = ET.parse(sys.stdin)\\nroot = tree.getroot()\\nfor article in root.findall('.//PubmedArticle'):\\n pmid = article.find('.//PMID').text\\n title = article.find('.//ArticleTitle').text\\n abstract_parts = article.findall('.//AbstractText')\\n full_abstract = ' '.join([a.text or '' for a in abstract_parts])\\n journal = article.find('.//Journal/Title').text\\n year = article.find('.//PubDate/Year').text\\n print(f'=== PMID: {pmid} | {journal} ({year}) ===')\\n print(f'Title: {title}')\\n print(f'Abstract: {full_abstract[:500]}')\\n print()\\n\\\" 2\\u003e\\u00261\",\"timeout\":20}" } }, { "id": "call_x120ewyx", "call_id": "call_x120ewyx", "response_item_id": "fc_x120ewyx", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed\\u0026id=20806989,28953649\\u0026rettype=abstract\\u0026retmode=xml\\\" 2\\u003e\\u00261 | python3 -c \\\"\\nimport sys, xml.etree.ElementTree as ET\\ntree = ET.parse(sys.stdin)\\nroot = tree.getroot()\\nfor article in root.findall('.//PubmedArticle'):\\n pmid = article.find('.//PMID').text\\n title = article.find('.//ArticleTitle').text\\n abstract_parts = article.findall('.//AbstractText')\\n full_abstract = ' '.join([a.text or '' for a in abstract_parts])\\n journal = article.find('.//Journal/Title').text\\n year = article.find('.//PubDate/Year').text\\n print(f'=== PMID: {pmid} | {journal} ({year}) ===')\\n print(f'Title: {title}')\\n print(f'Abstract: {full_abstract}')\\n print()\\n\\\" 2\\u003e\\u00261\",\"timeout\":20}" } }, { "id": "call_ar2v14p4", "call_id": "call_ar2v14p4", "response_item_id": "fc_ar2v14p4", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=10\\u0026term=escitalopram+withdrawal+discontinuation+syndrome+dose+taper\\\" 2\\u003e\\u00261\",\"timeout\":15}" } } ] }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"=== PMID: 31977667 | Menopause (New York, N.Y.) (2020) ===\\nTitle: Lights on MsFLASH: a review of contributions.\\nAbstract: The Menopause Strategies: Finding Lasting Answers for Symptoms and Health clinical trials network was funded by the National Institutes of Health to find new ways to alleviate the most common, bothersome menopausal symptoms by designing and conducting multiple concurrent clinical intervention studies, accommodating a wide scope of populations and intervention strategies. Trials were conducted in Boston, Indianapolis, Minneapolis, Oakland, Philadelphia, and Seattle, with the Data Coordinating Cen\\n\\n=== PMID: 29588433 | East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan (2018) ===\\nTitle: Sexual Dysfunction in Patients with Antidepressant-treated Anxiety or Depressive Disorders: a Pragmatic Multivariable Longitudinal Study.\\nAbstract: To investigate early evolution, tolerability, and predictors of antidepressant-emergent sexual dysfunction in patients with anxiety or depressive disorder. Patients with anxiety or depressive disorders who were prescribed antidepressant monotherapy (mirtazapine, sertraline, desvenlafaxine, escitalopram, or fluoxetine) at the discretion of the treating clinician were recruited from July 2012 to June 2014 from a hospital outpatient service. All were free of psychotropic medication for least 1 mont\\n\\n=== PMID: 29034101 | BJPsych open (2017) ===\\nTitle: Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review.\\nAbstract: Optimal anti-epileptic drug (AED) treatment maximises therapeutic response and minimises adverse effects (AEs). Key to therapeutic AED treatment is adherence. Non-adherence is often related to severity of AEs. Frequently, patients do not spontaneously report, and clinicians do not specifically query, critical AEs that lead to non-adherence, including sexual dysfunction. Sexual dysfunction prevalence in patients with epilepsy ranges from 40 to 70%, often related to AEDs, epilepsy or mood states. \\n\\n=== PMID: 23094470 | International journal of psychiatry in medicine (2012) ===\\nTitle: Sexual arousal difficulties in women treated with antidepressants: a comparison between escitalopram and fluoxetine.\\nAbstract: To compare the risk of sexual arousal difficulties between two groups of depressed female patients in remission who were treated with either escitalopram or fluoxetine. Associated factors were also examined. This was a cross-sectional study involving 112 female patients attending the psychiatric clinic, University Kebangsaan Malaysia Medical Centre (UKMMC) with depressive disorders as assessed by using the Structured Clinical Interview for DSM-IV (SCID), who had been in remission for the previou\\n\\n=== PMID: 22122658 | International journal of psychiatry in clinical practice (2012) ===\\nTitle: Hypoactive sexual desire among depressed female patients treated with selective serotonin reuptake inhibitors: a comparison between escitalopram and fluoxetine.\\nAbstract: To determine the risk of hypoactive sexual desire (HSD) in depressed female patients treated with selective serotonin reuptake inhibitors, comparing escitalopram and fluoxetine. The associated factors were also examined. This cross-sectional study involved 112 female patients (56 in each group) diagnosed to have major depressive disorder who were in remission (as defined by the Diagnostic and Statistical Manual-IV (DSM-IV) in the past 2 months and the Montgomery-Asberg Depression Rating Scale (M\\n\\n=== PMID: 21477024 | The journal of sexual medicine (2012) ===\\nTitle: Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.\\nAbstract: Selective serotonin reuptake inhibitor is one of the most widely used antidepressant and commonly associated with female sexual dysfunction (FSD). This study compares the prevalence of FSD between patients on escitalopram and fluoxetine. The risk factors for FSD were also examined. A cross-sectional study involved 112 female depressed patients (56 each group) who were in remission (as defined in the fourth edition of Diagnostic and Statistical Manual of Mental Disorders [DSM-IV] during the past \\n\\n=== PMID: 17627739 | The journal of sexual medicine (2007) ===\\nTitle: Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.\\nAbstract: Depression and antidepressant therapy have been associated with sexual dysfunction in short-term and point-prevalence trials. This report describes effects of duloxetine and escitalopram on sexual functioning during acute and long-term treatment of major depressive disorder (MDD). In this 8-month, double-blind, placebo-controlled study, adult outpatients with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)-defined MDD were randomized to duloxetine 60 mg/day (N = 273; \\n\\n=== PMID: 16528138 | International clinical psychopharmacology (2006) ===\\nTitle: A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.\\nAbstract: This multinational, randomized, double-blind, flexible-dose study evaluated the short- and long-term antidepressant tolerability and efficacy of escitalopram and paroxetine. Tolerability was assessed by monitoring adverse events throughout the study, and discontinuation events during brief treatment interruption and tapered withdrawal. Discontinuation-emergent effects were evaluated in two separate double-blind periods. First, to mimic the consequences of non-compliance, patients were randomized\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_negv2oul" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"=== PMID: 20806989 | CNS drugs (2010) ===\\nTitle: Escitalopram: a review of its use in the management of major depressive disorder in adults.\\nAbstract: Escitalopram (escitalopram oxalate; Cipralex, Lexapro), a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD), demonstrates a highly selective and potent, dose-dependent inhibition of the human serotonin transporter, inhibiting serotonin reuptake into presynaptic nerve terminals and thus increasing serotonergic activity in the CNS. With regard to primary endpoints (such as improved scores on the Montgomery-Asberg Depression Rating Scale [MADRS] and the Hamilton Depression Rating Scale [HAM-D]), escitalopram was generally more effective than placebo, at least as effective as citalopram, and generally at least as effective as other comparator drugs, including the SSRIs fluoxetine, paroxetine and sertraline, the serotonin-noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) venlafaxine extended release and duloxetine, and the aminoketone bupropion in adult patients with MDD in short-term, well designed trials. Moreover, it demonstrated a rapid onset of antidepressant action. Escitalopram was also found to be cost effective in several studies, dominating other SSRIs and venlafaxine extended release. Maintenance therapy is commonly required to prevent recurrence of depression. Long-term trials corroborated short-term results, with escitalopram demonstrating greater efficacy than placebo in relapse prevention. Additionally, escitalopram was at least as effective as citalopram, paroxetine and duloxetine in long-term comparative trials. Escitalopram has a predictable tolerability profile with generally mild to moderate and transient adverse events, and a low propensity for drug interactions. Sexual dysfunction with escitalopram treatment appeared to occur to a similar or lower extent to that with paroxetine (another SSRI), to a similar or greater extent to that with the SNRI duloxetine, and to a greater extent than that with the aminoketone bupropion. Thus, escitalopram is an effective and generally well tolerated treatment for moderate to severe MDD. Escitalopram, like other SSRIs, is an effective first-line option in the management of patients with MDD.\\n\\n=== PMID: 28953649 | Medicine (2017) ===\\nTitle: Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: A pooled analysis of 4 Chinese clinical trials.\\nAbstract: This study aimed to evaluate the efficacy of escitalopram monotherapy in the treatment of major depressive disorder (MDD) on the basis of pooled data analysis of 4 Chinese clinical trials.A total of 649 outpatients with MDD score of ≥18 at the 17-item Hamilton Depression Rating Scale (HAMD17) were included across 4 eligible studies. Patients were treated with 10 mg/day escitalopram for 2 weeks, and then 20 mg/day escitalopram was administered if the clinical response was poor.The change in total HAMD17 score was significantly greater in moderate MDD group than in other subgroups (P < .001), but the proportion of responders and remission rate in moderate MDD group were markedly lower than in mild MDD group. As compared to patients with concomitant anxiety, anxiety free patients showed significant improvement in total HAMD17 score at days 14 and 28 (P < .05). However, there was no significant difference in the change of total HAMD17 score at day 7 and the end of study. According to clinical global impression (CGI) score, the total response rate (very much improved and much improved) was 86.7%. There were 479 adverse events (AEs), but serious AEs were not observed. A total of 3.39% (22/649) of patients withdrew from these studies due to AEs. The most common (incidence ≥2.0%) AEs were nausea, dry mouth, somnolence, dizziness, fatigue, dyspepsia, liver dysfunction, and loss of appetite.Escitalopram monotherapy is effective and safe in the treatment of MDD in Chinese patients, and therapeutic efficacy is dependent on the severity of MDD. Further study is needed to identify better predictors of therapeutic responses.\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_x120ewyx" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n330\\n38851198\\n27171568\\n25721705\\n escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] withdrawal \\\"withdraw\\\"[All Fields] OR \\\"withdrawal\\\"[All Fields] OR \\\"withdrawals\\\"[All Fields] OR \\\"withdrawing\\\"[All Fields] OR \\\"withdraws\\\"[All Fields] discontinuation \\\"discontinuance\\\"[All Fields] OR \\\"discontinuances\\\"[All Fields] OR \\\"discontinuated\\\"[All Fields] OR \\\"discontinuation\\\"[All Fields] OR \\\"discontinuations\\\"[All Fields] OR \\\"discontinue\\\"[All Fields] OR \\\"discontinued\\\"[All Fields] OR \\\"discontinuer\\\"[All Fields] OR \\\"discontinuers\\\"[All Fields] OR \\\"discontinues\\\"[All Fields] OR \\\"discontinuing\\\"[All Fields] syndrome \\\"syndrom\\\"[All Fields] OR \\\"syndromal\\\"[All Fields] OR \\\"syndromally\\\"[All Fields] OR \\\"syndrome\\\"[MeSH Terms] OR \\\"syndrome\\\"[All Fields] OR \\\"syndromes\\\"[All Fields] OR \\\"syndrome's\\\"[All Fields] OR \\\"syndromic\\\"[All Fields] OR \\\"syndroms\\\"[All Fields] dose taper \\\"drug tapering\\\"[MeSH Terms] OR (\\\"drug\\\"[All Fields] AND \\\"tapering\\\"[All Fields]) OR \\\"drug tapering\\\"[All Fields] OR (\\\"dose\\\"[All Fields] AND \\\"taper\\\"[All Fields]) OR \\\"dose taper\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND (\\\"withdraw\\\"[All Fields] OR \\\"withdrawal\\\"[All Fields] OR \\\"withdrawals\\\"[All Fields] OR \\\"withdrawing\\\"[All Fields] OR \\\"withdraws\\\"[All Fields]) AND (\\\"discontinuance\\\"[All Fields] OR \\\"discontinuances\\\"[All Fields] OR \\\"discontinuated\\\"[All Fields] OR \\\"discontinuation\\\"[All Fields] OR \\\"discontinuations\\\"[All Fields] OR \\\"discontinue\\\"[All Fields] OR \\\"discontinued\\\"[All Fields] OR \\\"discontinuer\\\"[All Fields] OR \\\"discontinuers\\\"[All Fields] OR \\\"discontinues\\\"[All Fields] OR \\\"discontinuing\\\"[All Fields]) AND (\\\"syndrom\\\"[All Fields] OR \\\"syndromal\\\"[All Fields] OR \\\"syndromally\\\"[All Fields] OR \\\"syndrome\\\"[MeSH Terms] OR \\\"syndrome\\\"[All Fields] OR \\\"syndromes\\\"[All Fields] OR \\\"syndrome s\\\"[All Fields] OR \\\"syndromic\\\"[All Fields] OR \\\"syndroms\\\"[All Fields]) AND (\\\"drug tapering\\\"[MeSH Terms] OR (\\\"drug\\\"[All Fields] AND \\\"tapering\\\"[All Fields]) OR \\\"drug tapering\\\"[All Fields] OR (\\\"dose\\\"[All Fields] AND \\\"taper\\\"[All Fields]) OR \\\"dose taper\\\"[All Fields])\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_ar2v14p4" }, { "role": "assistant", "content": "", "reasoning": "Let me now compile the research I've gathered. I have several key papers:\n\n1. **PMID 36936596** (BMJ Medicine, 2022) - The most important one: \"Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis.\" Key findings:\n - Standard daily doses defined as 10 mg escitalopram\n - 83% of reviews included data for studies ≤12 weeks (acute phase)\n - Of 39 reviews assessing efficacy, majority (n=26) indicated flat dose-response effects; standard doses were optimal for efficacy\n - Higher than standard daily doses were associated with higher dropout rates and greater incidence of adverse drug effects (nausea, sexual dysfunction, fatigue, anxiety)\n - Standard daily doses provide a favourable balance between efficacy, acceptability, and tolerability\n\n2. **PMID 20806989** (CNS Drugs, 2010) - Comprehensive review of escitalopram. Key findings:\n - Escitalopram demonstrates dose-dependent inhibition of serotonin transporter\n - Generally more effective than placebo, at least as effective as citalopram and other SSRIs\n - Rapid onset of antidepressant action\n - Maintenance therapy commonly required\n - Predictable tolerability profile with generally mild to moderate and transient adverse events\n - Sexual dysfunction: similar or lower than paroxetine, similar or greater than duloxetine, greater than bupropion\n\n3. **PMID 28953649** (Medicine, 2017) - Pooled analysis of 4 Chinese clinical trials:\n - Patients treated with 10 mg/day escitalopram for 2 weeks, then 20 mg/day if poor response\n - Most common AEs (≥2%): nausea, dry mouth, somnolence, dizziness, fatigue, dyspepsia, liver dysfunction, loss of appetite\n - 3.39% withdrew due to AEs\n\n4. **PMID 29588433** (2018) - Sexual dysfunction in antidepressant-treated patients - longitudinal study\n\n5. **PMID 17627739** (2007) - Sexual functioning with duloxetine, escitalopram, and placebo - 8-month study\n\n6. **PMID 16528138** (2006) - Discontinuation effects with escitalopram and paroxetine\n\n7. **PMID 38643950** (2024) - Long-term SSRI use associated with weight gain and altered lipid profiles\n\n8. **PMID 32656861** (2021) - Strategies to reduce antidepressant use - notes that 30-50% of long-term users have no evidence-based indication to continue\n\nNow let me also try to get some German-language resources and patient experience information.\n\nLet me also try to get the full abstract of the sexual dysfunction study and the discontinuation study.\n\nActually, I have enough to compile a comprehensive answer. Let me also try to get some information about the specific experience of going from 5mg to 10mg after long-term use. The key finding from the BMJ Medicine review is that 10mg IS the standard dose, and that higher doses don't provide more efficacy but do increase side effects. So going from 5mg (which is below standard) to 10mg (standard) is actually the recommended approach.\n\nLet me also try to get the full abstract of PMID 29588433 (sexual dysfunction study) and PMID 16528138 (discontinuation study).", "finish_reason": "tool_calls", "reasoning_content": "Let me now compile the research I've gathered. I have several key papers:\n\n1. **PMID 36936596** (BMJ Medicine, 2022) - The most important one: \"Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis.\" Key findings:\n - Standard daily doses defined as 10 mg escitalopram\n - 83% of reviews included data for studies ≤12 weeks (acute phase)\n - Of 39 reviews assessing efficacy, majority (n=26) indicated flat dose-response effects; standard doses were optimal for efficacy\n - Higher than standard daily doses were associated with higher dropout rates and greater incidence of adverse drug effects (nausea, sexual dysfunction, fatigue, anxiety)\n - Standard daily doses provide a favourable balance between efficacy, acceptability, and tolerability\n\n2. **PMID 20806989** (CNS Drugs, 2010) - Comprehensive review of escitalopram. Key findings:\n - Escitalopram demonstrates dose-dependent inhibition of serotonin transporter\n - Generally more effective than placebo, at least as effective as citalopram and other SSRIs\n - Rapid onset of antidepressant action\n - Maintenance therapy commonly required\n - Predictable tolerability profile with generally mild to moderate and transient adverse events\n - Sexual dysfunction: similar or lower than paroxetine, similar or greater than duloxetine, greater than bupropion\n\n3. **PMID 28953649** (Medicine, 2017) - Pooled analysis of 4 Chinese clinical trials:\n - Patients treated with 10 mg/day escitalopram for 2 weeks, then 20 mg/day if poor response\n - Most common AEs (≥2%): nausea, dry mouth, somnolence, dizziness, fatigue, dyspepsia, liver dysfunction, loss of appetite\n - 3.39% withdrew due to AEs\n\n4. **PMID 29588433** (2018) - Sexual dysfunction in antidepressant-treated patients - longitudinal study\n\n5. **PMID 17627739** (2007) - Sexual functioning with duloxetine, escitalopram, and placebo - 8-month study\n\n6. **PMID 16528138** (2006) - Discontinuation effects with escitalopram and paroxetine\n\n7. **PMID 38643950** (2024) - Long-term SSRI use associated with weight gain and altered lipid profiles\n\n8. **PMID 32656861** (2021) - Strategies to reduce antidepressant use - notes that 30-50% of long-term users have no evidence-based indication to continue\n\nNow let me also try to get some German-language resources and patient experience information.\n\nLet me also try to get the full abstract of the sexual dysfunction study and the discontinuation study.\n\nActually, I have enough to compile a comprehensive answer. Let me also try to get some information about the specific experience of going from 5mg to 10mg after long-term use. The key finding from the BMJ Medicine review is that 10mg IS the standard dose, and that higher doses don't provide more efficacy but do increase side effects. So going from 5mg (which is below standard) to 10mg (standard) is actually the recommended approach.\n\nLet me also try to get the full abstract of PMID 29588433 (sexual dysfunction study) and PMID 16528138 (discontinuation study).", "tool_calls": [ { "id": "call_bn7ushgw", "call_id": "call_bn7ushgw", "response_item_id": "fc_bn7ushgw", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed\\u0026id=29588433,16528138,17627739,32656861\\u0026rettype=abstract\\u0026retmode=xml\\\" 2\\u003e\\u00261 | python3 -c \\\"\\nimport sys, xml.etree.ElementTree as ET\\ntree = ET.parse(sys.stdin)\\nroot = tree.getroot()\\nfor article in root.findall('.//PubmedArticle'):\\n pmid = article.find('.//PMID').text\\n title = article.find('.//ArticleTitle').text\\n abstract_parts = article.findall('.//AbstractText')\\n full_abstract = ' '.join([a.text or '' for a in abstract_parts])\\n journal = article.find('.//Journal/Title').text\\n year = article.find('.//PubDate/Year').text\\n print(f'=== PMID: {pmid} | {journal} ({year}) ===')\\n print(f'Title: {title}')\\n print(f'Abstract: {full_abstract}')\\n print()\\n\\\" 2\\u003e\\u00261\",\"timeout\":20}" } }, { "id": "call_sxk458yr", "call_id": "call_sxk458yr", "response_item_id": "fc_sxk458yr", "type": "function", "function": { "name": "terminal", "arguments": "{\"command\":\"curl -sL \\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed\\u0026retmax=10\\u0026term=escitalopram+5mg+low+dose+maintenance+long+term\\\" 2\\u003e\\u00261\",\"timeout\":15}" } } ] }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"=== PMID: 29588433 | East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan (2018) ===\\nTitle: Sexual Dysfunction in Patients with Antidepressant-treated Anxiety or Depressive Disorders: a Pragmatic Multivariable Longitudinal Study.\\nAbstract: To investigate early evolution, tolerability, and predictors of antidepressant-emergent sexual dysfunction in patients with anxiety or depressive disorder. Patients with anxiety or depressive disorders who were prescribed antidepressant monotherapy (mirtazapine, sertraline, desvenlafaxine, escitalopram, or fluoxetine) at the discretion of the treating clinician were recruited from July 2012 to June 2014 from a hospital outpatient service. All were free of psychotropic medication for least 1 month. Sexual function was assessed at baseline, week 2, and week 6 using the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ). A PRSexDQ score of ≥2 was considered to indicate sexual dysfunction. Sexual function was dichotomised to 'favourable' or 'impaired'. Of 230 patients recruited, 209 were assessed at baseline of whom 184 were assessed at week 2; of these, 154 were also assessed at week 6. At baseline, 138 (66%) of the 209 patients were diagnosed with depressive disorder and 71 (34%) with anxiety disorder; 29% of patients had sexual dysfunction (in any domain of PRSexDQ). By week 6, the percentage had increased to 41%, although the change in the mean PRSexDQ score was only marginal (from 1.04 at baseline to 1.55 at week 6). With regard to individual questionnaire items, by week 6, sexual desire improved, but erectile and ejaculatory function in men and orgasmic function in women worsened. Fluoxetine and sertraline were associated with impaired sexual function, whereas mirtazapine was associated with favourable sexual function. In a logistic regression analysis, at week 2, mirtazapine and desvenlafaxine were predictors of favourable sexual outcome, whereas fluoxetine and higher baseline PRSexDQ score were predictors of impaired sexual outcome. At week 6, mirtazapine remained a predictor of favourable sexual outcome, whereas fluoxetine, higher 2-week PRSexDQ score, and adequate dose were predictors of impaired sexual outcome. In patients with anxiety or depressive disorder, the risk of antidepressant-emergent sexual dysfunction at 6 weeks is low when drug doses are initially low with gradual up-titration. Baseline sexual dysfunction was independently associated with impaired sexual outcome. Men may be more likely than women to experience impaired sexual outcome. In patients with baseline sexual dysfunction, prescription of mirtazapine might be preferable to fluoxetine.\\n\\n=== PMID: 16528138 | International clinical psychopharmacology (2006) ===\\nTitle: A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.\\nAbstract: This multinational, randomized, double-blind, flexible-dose study evaluated the short- and long-term antidepressant tolerability and efficacy of escitalopram and paroxetine. Tolerability was assessed by monitoring adverse events throughout the study, and discontinuation events during brief treatment interruption and tapered withdrawal. Discontinuation-emergent effects were evaluated in two separate double-blind periods. First, to mimic the consequences of non-compliance, patients were randomized to one of two treatment interruption periods (placebo-substitution for 3-5 days). Second, patients were randomized to a 1-2-week tapered withdrawal period randomly scheduled between weeks 28 and 31. The pre-specified primary efficacy endpoint was the mean change from baseline in total Montgomery-Asberg Depression Rating Scale (MADRS) score at week 8, using the principle of last observation carried forward. A total of 323 patients entered 8 weeks of double-blind treatment and received at least one flexible dose of escitalopram (10-20 mg/day) or paroxetine (20-40 mg/day). Patients who demonstrated evidence of a significant clinical improvement (Clinical Global Impression-Improvement of 1 or 2) at week 8 entered a 19-week, double-blind maintenance period during which they were treated with the same dose they received at week 8, followed by a 1-2-week tapered withdrawal period. A total of 89 patients (28%) withdrew during the study; significantly (P<0.01) more patients withdrew from the paroxetine group (34%) than from the escitalopram group (21%), and significantly (P<0.05) more paroxetine patients withdrew due to lack of efficacy. The mean MADRS total score improved for both treatment groups from baseline to week 8, with no statistical difference between groups. In severely depressed patients (baseline MADRS total score >or=30), escitalopram was superior (P<0.05) to paroxetine at week 27 (end of maintenance treatment). There was a high prevalence of sexual dysfunction at baseline: the mean Arizona Sexual Experience Scale (ASEX) score was approximately 20 points in both treatment groups. Mean total ASEX scores increased slightly above baseline values during the acute period and declined slightly below baseline values towards the end of the maintenance period. During taper and cessation of treatment, patients in the paroxetine group demonstrated significantly more discontinuation symptoms relative to escitalopram based on the Discontinuation Emergent Signs and Symptoms scores.\\n\\n=== PMID: 17627739 | The journal of sexual medicine (2007) ===\\nTitle: Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.\\nAbstract: Depression and antidepressant therapy have been associated with sexual dysfunction in short-term and point-prevalence trials. This report describes effects of duloxetine and escitalopram on sexual functioning during acute and long-term treatment of major depressive disorder (MDD). In this 8-month, double-blind, placebo-controlled study, adult outpatients with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)-defined MDD were randomized to duloxetine 60 mg/day (N = 273; 173 female), escitalopram 10 mg/day (N = 274; 186 female), or placebo (N = 137; 87 female). After the first 8 weeks of treatment, dose increases were permitted to optimize treatment. The 14-item Changes in Sexual Functioning Questionnaire (CSFQ) was used to assess sexual functioning. Of the 114 patients who did not meet total CSFQ score criteria for global sexual dysfunction at baseline (duloxetine, N = 51; escitalopram, N = 39; placebo, N = 24), the incidence of treatment-emergent sexual dysfunction was significantly higher for escitalopram compared with placebo at 4 and 8 weeks, and significantly higher compared with duloxetine at 4 weeks. At 8 weeks, the incidence of treatment-emergent sexual dysfunction was 17/51 (33.3%) for duloxetine-treated patients; 19/39 (48.7%) for escitalopram-treated patients; and 4/24 (16.7%) for placebo-treated patients (P = 0.01 escitalopram vs. placebo; P = 0.13 duloxetine vs. placebo). After 12 weeks, no significant differences were observed between active drugs. At 8 months, the incidence of treatment-emergent sexual dysfunction was 33.3% for duloxetine, 43.6% for escitalopram, and 25.0% for placebo. Regardless of treatment, patients who achieved remission of MDD showed improvement in global sexual functioning, whereas worsening was observed for patients who did not achieve remission (P < 0.001). Discontinuation rates for sexual side effects did not differ between duloxetine (N = 2) and escitalopram (N = 7) (P = 0.07). Short-term treatment demonstrated a higher incidence of treatment-emergent sexual dysfunction with escitalopram compared with duloxetine and placebo. After 12 weeks, there were no statistically significant differences between drugs; however, MDD outcome (regardless of treatment) had a significant impact on improvement in global sexual functioning.\\n\\n=== PMID: 32656861 | British journal of clinical pharmacology (2021) ===\\nTitle: Strategies to reduce use of antidepressants.\\nAbstract: Antidepressant prescribing has increased year on year since the introduction of the selective serotonin reuptake inhibitors (SSRIs) in the 1980s. More than 10% of adults in England are now taking antidepressants for depression/anxiety, with a median length of treatment of more than 2 years, but antidepressants can cause side effects and withdrawal symptoms which increase with longer use. Surveys of antidepressant users suggest 30-50% have no evidence-based indication to continue, but coming off antidepressants is often difficult due to fears of relapse, withdrawal symptoms and a lack of psychological treatments to replace maintenance treatment and prevent relapse. GPs should not prescribe antidepressants routinely for mild depressive/anxiety symptoms. Patients starting antidepressants should be advised that they are to be taken for a limited period only, and that there is a risk of withdrawal problems on stopping them. Prescribers should actively review long-term antidepressant use and suggest coming off them slowly to patients who are well. The relationship between SSRI dose and serotonin transporter receptor occupancy suggests that hyperbolic tapering regimes may be helpful for patients with troubling withdrawal symptoms who cannot stop treatment within 4-8 weeks, and tapering strips can allow carefully titrated slower dose reduction over some months. Internet and telephone support to patients wanting to reduce their antidepressants is being trialled in the REDUCE programme. More research is needed to establish the incidence of withdrawal symptoms in representative samples of patients coming off antidepressants, and large randomised controlled trials are needed to test different tapering strategies.\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_bn7ushgw" }, { "role": "tool", "name": "terminal", "content": "{\"output\": \"\\n\\n000 escitalopram \\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram's\\\"[All Fields] maintenance \\\"maintenance\\\"[MeSH Terms] OR \\\"maintenance\\\"[All Fields] OR \\\"maintenances\\\"[All Fields] term \\\"term birth\\\"[MeSH Terms] OR (\\\"term\\\"[All Fields] AND \\\"birth\\\"[All Fields]) OR \\\"term birth\\\"[All Fields] OR \\\"term\\\"[All Fields] (\\\"escitalopram\\\"[Supplementary Concept] OR \\\"escitalopram\\\"[All Fields] OR \\\"escitalopram\\\"[MeSH Terms] OR \\\"escitalopram s\\\"[All Fields]) AND \\\"5mg\\\"[All Fields] AND \\\"low\\\"[All Fields] AND \\\"dose\\\"[All Fields] AND (\\\"maintenance\\\"[MeSH Terms] OR \\\"maintenance\\\"[All Fields] OR \\\"maintenances\\\"[All Fields]) AND \\\"long\\\"[All Fields] AND (\\\"term birth\\\"[MeSH Terms] OR (\\\"term\\\"[All Fields] AND \\\"birth\\\"[All Fields]) OR \\\"term birth\\\"[All Fields] OR \\\"term\\\"[All Fields])No items found.\", \"exit_code\": 0, \"error\": null}", "tool_call_id": "call_sxk458yr" }, { "role": "assistant", "content": "Hier ist die ausführliche Recherche, basierend auf PubMed-Studien und systematischen Reviews.\n\n---\n\n## Systematischer Review: Dosis-Wirkungs-Beziehung bei SSRIs\n\n**BMJ Medicine (2022) — PMID 36936596** \n*Dose-response effects of SSRI monotherapy for depression: systematic review of reviews*\n\nDas ist die aktuellste und umfassendste Meta-Übersicht (42 eingeschlossene Reviews, 1975–2021). Kernbefunde:\n\n- **Flache Dosis-Wirkungs-Kurve:** 83 % der Reviews zeigen: Für die antidepressive Wirksamkeit bringen höhere Dosen *keinen* nennenswerten Zusatznutzen. Die Standarddosis — für Escitalopram **10 mg/Tag** — ist optimal.\n- **Höhere Dosen = mehr Nebenwirkungen + mehr Abbrüche:** Über der Standarddosis steigen Dropout-Raten und Nebenwirkungen signifikant an (Übelkeit, sexuelle Dysfunktion, Fatigue, Angst).\n- **Fazit der Autoren:** 10 mg Escitalopram bietet die günstigste Balance zwischen Wirkung, Verträglichkeit und Therapietreue.\n\n---\n\n## Escitalopram 10 mg: Wirksamkeit & Verträglichkeit\n\n**CNS Drugs (2010) — PMID 20806989** \n*Umfassender Review zu Escitalopram bei MDD*\n\n- 10 mg ist die etablierte therapeutische Standarddosis\n- Wirkt Placebo überlegen, mindestens gleichwertig zu Citalopram, Fluoxetin, Paroxetin, Sertralin, Venlafaxin, Duloxetin\n- Nebenwirkungen: meist mild-moderat und transient\n- Sexuelle Dysfunktion: ähnlich oder geringer als Paroxetin, aber stärker als Duloxetin und Bupropion\n\n**Medicine (2017) — PMID 28953649** \n*Gepoolte Analyse von 4 chinesischen Studien (n=649)*\n\n- 10 mg/Tag für 2 Wochen, dann 20 mg bei Poor Response\n- Häufigste Nebenwirkungen (≥2 %): Übelkeit, Mundtrockenheit, Schläfrigkeit, Schwindel, Fatigue, Dyspepsie, Leberwerterhöhung, Appetitverlust\n- 3,39 % brachen wegen Nebenwirkungen ab\n- Keine schwerwiegenden Nebenwirkungen\n\n---\n\n## Sexuelle Dysfunktion — der dosisabhängige Hauptfaktor\n\n**Journal of Sexual Medicine (2007) — PMID 17627739** \n*8-Monate-Doppelblindstudie: Duloxetin vs. Escitalopram 10 mg vs. Placebo (n=684)*\n\n- **Behandlungsbedingte sexuelle Dysfunktion unter Escitalopram 10 mg:**\n - Nach 8 Wochen: **48,7 %**\n - Nach 8 Monaten: **43,6 %**\n - Placebo: 16,7 % / 25,0 %\n- Wichtig: Patienten, die eine **Remission** erreichten, zeigten *Verbesserung* der sexuellen Funktion — unabhängig vom Medikament. Wer nicht remittierte, verschlechterte sich.\n\n**East Asian Archives of Psychiatry (2018) — PMID 29588433** \n*Longitudinalstudie zu Antidepressiva-emergenter sexueller Dysfunktion (n=184)*\n\n- Nach 6 Wochen: 41 % sexuelle Dysfunktion (von 29 % bei Baseline)\n- **Prädiktoren für sexuelle Dysfunktion in Woche 6:** Fluoxetin, höherer Score in Woche 2, und **\"adequate dose\" (ausreichend hohe Dosis)**\n- **Schutzfaktor:** Niedrige Anfangsdosis mit gradueller Auftitration\n\n---\n\n## Absetzsymptome & Langzeiteffekte\n\n**British Journal of Clinical Pharmacology (2021) — PMID 32656861** \n*Strategien zur Reduktion von Antidepressiva*\n\n- Nebenwirkungen und Absetzsymptome **nehmen mit längerer Einnahmedauer zu**\n- Median der Einnahmedauer in England: >2 Jahre\n- 30–50 % der Langzeitnutzer haben keine evidenzbasierte Indikation mehr\n- Empfehlung: **Hyperbolisches Tapering** (prozentuale Dosisreduktion statt linearer Schritte), da die SERT-Rezeptorbesetzung nicht linear zur Dosis abfällt\n\n**International Clinical Psychopharmacology (2006) — PMID 16528138** \n*Escitalopram vs. Paroxetin: Absetzsymptome*\n\n- Escitalopram verursacht **signifikant weniger Absetzsymptome** als Paroxetin\n- Sexuelle Dysfunktion war schon bei Baseline hoch (ASEX ~20), stieg in der Akutphase leicht an und **sank in der Erhaltungsphase unter den Baseline-Wert**\n\n---\n\n## Synthese: Was das für dich bedeutet (3 Jahre auf 5 mg → 10 mg)\n\n| Aspekt | Erwartung |\n|---|---|\n| **Wirksamkeit** | 10 mg ist die Standarddosis mit optimaler Efficacy. Der Sprung von 5 auf 10 mg *kann* wirksamer sein — aber die Dosis-Wirkungs-Kurve ist flach, d.h. der Zugewinn ist nicht dramatisch |\n| **Anfangs-Nebenwirkungen** | Da du schon 3 Jahre adaptiert bist, dürfte die Akutphase (Übelkeit, Unruhe) milder sein als bei Neueinsteigern — aber nicht null |\n| **Sexuelle Dysfunktion** | Das ist der wahrscheinlichste *neue* oder *verstärkte* Effekt. Die Inzidenz unter 10 mg liegt bei ~40–50 %. Die Studien zeigen klar: höhere Dosis = höheres Risiko |\n| **Emotionale Abstumpfung** | Dazu gibt es weniger harte Daten, aber klinisch ist das dosisabhängig beschrieben |\n| **Absetzbarkeit später** | Je länger und höher dosiert, desto schwieriger das Absetzen. Hyperbolisches Tapering wäre der Weg |\n\n**Die zentrale Frage aus der Evidenz:** Brauchst du wirklich 10 mg? Die Studienlage sagt: Wenn 5 mg dich 3 Jahre stabil gehalten hat und du *jetzt* eine Symptomverschlechterung hast, ist die Erhöhung plausibel. Wenn du aber stabil bist und \"mehr\" willst — die Daten stützen das nicht. 10 mg ist nicht \"doppelt so gut\", sondern bringt vor allem mehr Nebenwirkungspotential.\n\n---\n\n**Nochmal der obligatorische Hinweis:** Das ist Literatur-Recherche, keine individuelle medizinische Empfehlung. Die Entscheidung trifft dein Arzt.", "reasoning": "Let me now compile the research findings into a comprehensive response. I have gathered substantial evidence from PubMed:\n\n1. **BMJ Medicine 2022 (PMID 36936596)** - Systematic review of SSRI dose-response: Standard doses (10mg escitalopram) provide optimal balance between efficacy, acceptability, and tolerability. Higher doses associated with more dropouts and adverse effects (nausea, sexual dysfunction, fatigue, anxiety). Flat dose-response curve for efficacy.\n\n2. **CNS Drugs 2010 (PMID 20806989)** - Comprehensive escitalopram review: 10mg is standard dose, effective and well-tolerated. Sexual dysfunction occurs.\n\n3. **Medicine 2017 (PMID 28953649)** - Pooled analysis of 4 Chinese trials: 10mg/day escitalopram for 2 weeks, then 20mg if poor response. Most common AEs: nausea, dry mouth, somnolence, dizziness, fatigue, dyspepsia, liver dysfunction, loss of appetite. 3.39% withdrew due to AEs.\n\n4. **J Sexual Medicine 2007 (PMID 17627739)** - 8-month study: escitalopram 10mg vs duloxetine vs placebo. Treatment-emergent sexual dysfunction: 48.7% for escitalopram at 8 weeks, 43.6% at 8 months. Patients achieving remission showed improvement in sexual functioning regardless of treatment.\n\n5. **East Asian Archives 2018 (PMID 29588433)** - Sexual dysfunction study: At week 6, 41% had sexual dysfunction. \"Adequate dose\" was predictor of impaired sexual outcome. Low initial doses with gradual up-titration reduced risk.\n\n6. **Int Clin Psychopharmacology 2006 (PMID 16528138)** - Escitalopram 10-20mg vs paroxetine 20-40mg. High baseline sexual dysfunction (ASEX ~20). Scores increased during acute phase, declined below baseline during maintenance. Escitalopram had fewer discontinuation symptoms than paroxetine.\n\n7. **Brit J Clin Pharmacology 2021 (PMID 32656861)** - Strategies to reduce antidepressant use: Side effects and withdrawal symptoms increase with longer use. Hyperbolic tapering recommended.\n\nNow let me synthesize this into a comprehensive, well-structured response for the user. Key points:\n\n- The BMJ 2022 systematic review is the most authoritative: 10mg is the standard/optimal dose for escitalopram. Higher doses don't improve efficacy much but increase side effects.\n- Sexual dysfunction is dose-dependent and significant (~40-50% incidence at 10mg)\n- The 2018 study specifically says low initial doses with gradual up-titration reduce sexual dysfunction risk\n- Common side effects at 10mg: nausea, dry mouth, somnolence, dizziness, fatigue\n- After 3 years on 5mg, the user is in a unique position - long-term low-dose maintenance\n- The hyperbolic tapering concept from the 2021 paper is relevant if they ever want to come off\n\nI should present this clearly with citations.", "finish_reason": "stop", "reasoning_content": "Let me now compile the research findings into a comprehensive response. I have gathered substantial evidence from PubMed:\n\n1. **BMJ Medicine 2022 (PMID 36936596)** - Systematic review of SSRI dose-response: Standard doses (10mg escitalopram) provide optimal balance between efficacy, acceptability, and tolerability. Higher doses associated with more dropouts and adverse effects (nausea, sexual dysfunction, fatigue, anxiety). Flat dose-response curve for efficacy.\n\n2. **CNS Drugs 2010 (PMID 20806989)** - Comprehensive escitalopram review: 10mg is standard dose, effective and well-tolerated. Sexual dysfunction occurs.\n\n3. **Medicine 2017 (PMID 28953649)** - Pooled analysis of 4 Chinese trials: 10mg/day escitalopram for 2 weeks, then 20mg if poor response. Most common AEs: nausea, dry mouth, somnolence, dizziness, fatigue, dyspepsia, liver dysfunction, loss of appetite. 3.39% withdrew due to AEs.\n\n4. **J Sexual Medicine 2007 (PMID 17627739)** - 8-month study: escitalopram 10mg vs duloxetine vs placebo. Treatment-emergent sexual dysfunction: 48.7% for escitalopram at 8 weeks, 43.6% at 8 months. Patients achieving remission showed improvement in sexual functioning regardless of treatment.\n\n5. **East Asian Archives 2018 (PMID 29588433)** - Sexual dysfunction study: At week 6, 41% had sexual dysfunction. \"Adequate dose\" was predictor of impaired sexual outcome. Low initial doses with gradual up-titration reduced risk.\n\n6. **Int Clin Psychopharmacology 2006 (PMID 16528138)** - Escitalopram 10-20mg vs paroxetine 20-40mg. High baseline sexual dysfunction (ASEX ~20). Scores increased during acute phase, declined below baseline during maintenance. Escitalopram had fewer discontinuation symptoms than paroxetine.\n\n7. **Brit J Clin Pharmacology 2021 (PMID 32656861)** - Strategies to reduce antidepressant use: Side effects and withdrawal symptoms increase with longer use. Hyperbolic tapering recommended.\n\nNow let me synthesize this into a comprehensive, well-structured response for the user. Key points:\n\n- The BMJ 2022 systematic review is the most authoritative: 10mg is the standard/optimal dose for escitalopram. Higher doses don't improve efficacy much but increase side effects.\n- Sexual dysfunction is dose-dependent and significant (~40-50% incidence at 10mg)\n- The 2018 study specifically says low initial doses with gradual up-titration reduce sexual dysfunction risk\n- Common side effects at 10mg: nausea, dry mouth, somnolence, dizziness, fatigue\n- After 3 years on 5mg, the user is in a unique position - long-term low-dose maintenance\n- The hyperbolic tapering concept from the 2021 paper is relevant if they ever want to come off\n\nI should present this clearly with citations." }, { "role": "user", "content": "Review the conversation above and update the skill library. Be ACTIVE — most sessions produce at least one skill update, even if small. A pass that does nothing is a missed learning opportunity, not a neutral outcome.\n\nTarget shape of the library: CLASS-LEVEL skills, each with a rich SKILL.md and a `references/` directory for session-specific detail. Not a long flat list of narrow one-session-one-skill entries. This shapes HOW you update, not WHETHER you update.\n\nSignals to look for (any one of these warrants action):\n • User corrected your style, tone, format, legibility, or verbosity. Frustration signals like 'stop doing X', 'this is too verbose', 'don't format like this', 'why are you explaining', 'just give me the answer', 'you always do Y and I hate it', or an explicit 'remember this' are FIRST-CLASS skill signals, not just memory signals. Update the relevant skill(s) to embed the preference so the next session starts already knowing.\n • User corrected your workflow, approach, or sequence of steps. Encode the correction as a pitfall or explicit step in the skill that governs that class of task.\n • Non-trivial technique, fix, workaround, debugging path, or tool-usage pattern emerged that a future session would benefit from. Capture it.\n • A skill that got loaded or consulted this session turned out to be wrong, missing a step, or outdated. Patch it NOW.\n\nPreference order — prefer the earliest action that fits, but do pick one when a signal above fired:\n 1. UPDATE A CURRENTLY-LOADED SKILL. Look back through the conversation for skills the user loaded via /skill-name or you read via skill_view. If any of them covers the territory of the new learning, PATCH that one first. It is the skill that was in play, so it's the right one to extend.\n 2. UPDATE AN EXISTING UMBRELLA (via skills_list + skill_view). If no loaded skill fits but an existing class-level skill does, patch it. Add a subsection, a pitfall, or broaden a trigger.\n 3. ADD A SUPPORT FILE under an existing umbrella. Skills can be packaged with three kinds of support files — use the right directory per kind:\n • `references/.md` — session-specific detail (error transcripts, reproduction recipes, provider quirks) AND condensed knowledge banks: quoted research, API docs, external authoritative excerpts, or domain notes you found while working on the problem. Write it concise and for the value of the task, not as a full mirror of upstream docs.\n • `templates/.` — starter files meant to be copied and modified (boilerplate configs, scaffolding, a known-good example the agent can `reproduce with modifications`).\n • `scripts/.` — statically re-runnable actions the skill can invoke directly (verification scripts, fixture generators, deterministic probes, anything the agent should run rather than hand-type each time).\n Add support files via skill_manage action=write_file with file_path starting 'references/', 'templates/', or 'scripts/'. The umbrella's SKILL.md should gain a one-line pointer to any new support file so future agents know it exists.\n 4. CREATE A NEW CLASS-LEVEL UMBRELLA SKILL when no existing skill covers the class. The name MUST be at the class level. The name MUST NOT be a specific PR number, error string, feature codename, library-alone name, or 'fix-X / debug-Y / audit-Z-today' session artifact. If the proposed name only makes sense for today's task, it's wrong — fall back to (1), (2), or (3).\n\nUser-preference embedding (important): when the user expressed a style/format/workflow preference, the update belongs in the SKILL.md body, not just in memory. Memory captures 'who the user is and what the current situation and state of your operations are'; skills capture 'how to do this class of task for this user'. When they complain about how you handled a task, the skill that governs that task needs to carry the lesson.\n\nIf you notice two existing skills that overlap, note it in your reply — the background curator handles consolidation at scale.\n\n'Nothing to save.' is a real option but should NOT be the default. If the session ran smoothly with no corrections and produced no new technique, just say 'Nothing to save.' and stop. Otherwise, act." }, { "role": "assistant", "content": "", "reasoning": "Let me review the conversation carefully to identify any signals for skill updates.\n\nThe conversation was about:\n1. User asking about Cipralex (Escitalopram) dose increase from 5mg to 10mg\n2. I gave initial answers based on general knowledge\n3. User asked me to research extensively on the internet\n4. I tried multiple search approaches (DuckDuckGo HTML, Startpage, DuckDuckGo API, Wikipedia API) - all returned empty\n5. I switched to PubMed (NCBI E-Utilities) which worked well\n6. I fetched multiple relevant papers and synthesized findings\n\nSignals to look for:\n- User corrections to style/tone/format? No explicit corrections in this conversation.\n- Non-trivial technique emerged? YES - the PubMed search workflow. Web search APIs failed, but PubMed's E-Utilities (esearch + efetch) worked reliably. This is a valuable research technique.\n- Skills loaded? None were explicitly loaded for this task. I didn't use skill_view for any skill.\n- User preferences? The user didn't express frustration or corrections here.\n\nThe key learning from this session: When web search (DuckDuckGo, Startpage) returns empty results, PubMed's E-Utilities API is a reliable fallback for medical/scientific research queries. The workflow of esearch → efetch → parse XML abstracts is a proven pattern.\n\nThis could be added to the `academic-research` skill or the `research` category. Let me check what skills exist in the research category.\n\nLooking at available skills:\n- `academic-research`: \"Research professors, extract/publications, analyze resear...\"\n- `arxiv`: \"Search arXiv papers by keyword, author, category, or ID.\"\n\nThe `academic-research` skill seems like the right umbrella. Let me load it to see if PubMed is already covered.\n\nActually, I should also consider: the user didn't load any skill for this task. The research workflow I used (PubMed API) is a technique that could benefit future sessions. Let me check the academic-research skill first.\n\nAlso, I should note: the user's preference for \"concise technical reports\" is already in memory. The response format I gave (synthesized research with clear sections, bullet points, and a summary table) seemed to work well - no complaints.\n\nLet me load the academic-research skill to see if PubMed is covered.", "finish_reason": "tool_calls", "reasoning_content": "Let me review the conversation carefully to identify any signals for skill updates.\n\nThe conversation was about:\n1. User asking about Cipralex (Escitalopram) dose increase from 5mg to 10mg\n2. I gave initial answers based on general knowledge\n3. User asked me to research extensively on the internet\n4. I tried multiple search approaches (DuckDuckGo HTML, Startpage, DuckDuckGo API, Wikipedia API) - all returned empty\n5. I switched to PubMed (NCBI E-Utilities) which worked well\n6. I fetched multiple relevant papers and synthesized findings\n\nSignals to look for:\n- User corrections to style/tone/format? No explicit corrections in this conversation.\n- Non-trivial technique emerged? YES - the PubMed search workflow. Web search APIs failed, but PubMed's E-Utilities (esearch + efetch) worked reliably. This is a valuable research technique.\n- Skills loaded? None were explicitly loaded for this task. I didn't use skill_view for any skill.\n- User preferences? The user didn't express frustration or corrections here.\n\nThe key learning from this session: When web search (DuckDuckGo, Startpage) returns empty results, PubMed's E-Utilities API is a reliable fallback for medical/scientific research queries. The workflow of esearch → efetch → parse XML abstracts is a proven pattern.\n\nThis could be added to the `academic-research` skill or the `research` category. Let me check what skills exist in the research category.\n\nLooking at available skills:\n- `academic-research`: \"Research professors, extract/publications, analyze resear...\"\n- `arxiv`: \"Search arXiv papers by keyword, author, category, or ID.\"\n\nThe `academic-research` skill seems like the right umbrella. Let me load it to see if PubMed is already covered.\n\nActually, I should also consider: the user didn't load any skill for this task. The research workflow I used (PubMed API) is a technique that could benefit future sessions. Let me check the academic-research skill first.\n\nAlso, I should note: the user's preference for \"concise technical reports\" is already in memory. The response format I gave (synthesized research with clear sections, bullet points, and a summary table) seemed to work well - no complaints.\n\nLet me load the academic-research skill to see if PubMed is covered.", "tool_calls": [ { "id": "call_6fqiyxbo", "call_id": "call_6fqiyxbo", "response_item_id": "fc_6fqiyxbo", "type": "function", "function": { "name": "skill_view", "arguments": "{\"name\":\"academic-research\"}" } } ] }, { "role": "tool", "name": "skill_view", "content": "{\"success\": true, \"name\": \"academic-research\", \"description\": \"Research professors, extract/publications, analyze research interests, and develop thesis/Bachelorarbeit topics — optimized for Austrian legal academia (WU Wien, RIS, Jina.ai workaround).\", \"tags\": [], \"related_skills\": [], \"content\": \"---\\nname: academic-research\\ndescription: Research professors, extract/publications, analyze research interests, and develop thesis/Bachelorarbeit topics — optimized for Austrian legal academia (WU Wien, RIS, Jina.ai workaround).\\n---\\n\\n# Academic Research — Professor & Thesis Research\\n\\nResearch workflow for academic tasks: profile a professor, extract their publications, analyze research focus, and develop thesis topics that align with their expertise.\\n\\n## Triggers\\n\\n- Researching a professor (profile, publications, research interests)\\n- Finding sources/literature for a Bachelorarbeit, Masterarbeit, or seminar paper\\n- Analyzing publication history to predict which topics a professor would supervise\\n- Extracting publications from university websites (especially WU Wien)\\n\\n---\\n\\n## Step 1: Find Professor Profile\\n\\nWU Wien uses SPA-based pages that return empty bodies to direct `curl`. Workaround:\\n\\n```\\ncurl -sL \\\"https://r.jina.ai/https://www.wu.ac.at/...\\\" -H \\\"Accept: text/plain\\\"\\n```\\n\\nStart from the institute page (`/unternehmensrecht/institut/...`) to discover the correct profile URL, then extract from the subpages:\\n- **Profile**: `/institut/.../prof-kalss` → name, title, email, phone, research areas\\n- **Publications**: `/institut/.../forschungsaktivitaeten` → massive list of books + articles\\n- **Abschlussarbeiten**: `/institut/.../abschlussarbeiten/bewerbung` → application procedure, deadlines\\n\\nPitfall: WU pages are navigation-heavy; Jina captures the full nav tree. Filter aggressively.\\n\\n---\\n\\n## Step 2: Extract Publications\\n\\nThe WU Forschungsaktivitäten page lists publications as:\\n\\n```\\n2025**Kalss, Susanne, Probst, Stephan.** 2025. Familienunternehmen. [Mehr erfahren](link)\\n```\\n\\n**Parsing approach** (Python):\\n\\n```python\\nimport re\\n\\n# Extract all year+block pairs\\npub_blocks = re.findall(r'(\\\\d{4})\\\\*\\\\*(.+?)(?=\\\\n\\\\d{4}\\\\*\\\\*|\\\\n##|\\\\Z)', text, re.DOTALL)\\n\\nfor year, block in pub_blocks:\\n block = re.sub(r'\\\\[Mehr erfahren\\\\]\\\\([^)]+\\\\)', '', block) # Remove links\\n lines = [l.strip() for l in block.split('\\\\n') if l.strip() and 'Kalss' in l]\\n for line in lines:\\n line = re.sub(r'\\\\*\\\\*', '', line)\\n is_book = 'In:' not in line and 'Hrsg.' not in line\\n # is_book → Monographie/Kommentar\\n # else → Aufsatz/Beitrag\\n```\\n\\nDeduplicate with a `set()` on the full line text.\\n\\n---\\n\\n## Step 3: Topic Analysis\\n\\nClassify publications into topic areas by keyword matching:\\n\\n```python\\ntopics = {\\n 'Gesellschaftsrecht': ['gesellschaftsrecht', 'aktg', 'gmbh', 'flexco', 'aktiengesellschaft', 'mehrstimmrecht'],\\n 'Aufsichtsrat': ['aufsichtsrat', 'corporate governance', 'beirat', 'compliance'],\\n 'Kapitalmarktrecht': ['kapitalmarkt', 'börse', 'anleger', 'wertpapier', 'übernahmerecht'],\\n 'Stiftungsrecht': ['stiftung', 'privatstiftung', 'stiftungsvorstand'],\\n 'Nachhaltigkeit/ESG': ['nachhaltigkeit', 'klima', 'csddd', 'lieferkette'],\\n # ... add more as needed\\n}\\n```\\n\\nCount per topic and per year; look for *recent* clusters (2023+) as indicators of active interest.\\n\\n---\\n\\n## Step 4: Topic Selection Strategy\\n\\nFor thesis topics that maximize acceptance chance:\\n\\n1. **Highest volume** → safest (professor has written most about this, you can cite them heavily)\\n2. **Recent activity** → highest interest (they're currently building this area)\\n3. **Cross-cutting topics** → best of both worlds (bridges two of their established fields)\\n\\nFor Kalss specifically:\\n- Aufsichtsrat: 91 publications, 44 since 2016 → safest\\n- Nachhaltigkeit/ESG: 11 publications, all from 2022–2025 → her current passion\\n- Mehrstimmrechte: 36 publications, co-authored with Hopt → prestige connection\\n\\n---\\n\\n## Austrian Legal Research: Source Strategy\\n\\n### RIS (Rechtsinformationssystem des Bundes) — DO NOT USE\\n\\nRIS at `ris.bka.gv.at` is **completely broken for programmatic access**. Every approach fails:\\n\\n- **GeltendeFassung.wxe** returns 404 for valid Gesetzesnummern (e.g. WEG 2002: 20000724) — \\\"nicht mehr oder noch nicht in Kraft\\\" even when the law is in force. Jina.ai captures only this error message.\\n- **Dokument.wxe** with NOR-nummer (e.g. NOR40252684) returns **random wrong documents** — an ABGB query returned \\\"Land- und forstwirtschaftliche Verordnung biologische Arbeitsstoffe § 10\\\"\\n- **ELI URLs** (`/eli/bgbl/I/2002/70/P13/...`) redirect to completely wrong laws (e.g. \\\"Limit-Verordnung 2012/13\\\" instead of WEG § 13)\\n- **OGH decision search** (`Ergebnis.wxe?Abfrage=Justiz`) returns ASP.NET ViewState pages — Geschäftszahlen and titles are buried in postback-dependent JavaScript, unextractable by curl or Jina\\n- **HTML-only URLs** (`/Dokumente/Bundesnormen/NOR.../NOR....html`) return 44 KB pages with zero text content after tag stripping — just navigation and JavaScript\\n- **Jina.ai** captures only the navigation sidebar, not document content, because RIS is a SPA that renders content client-side via ViewState postbacks\\n\\n### Workflow for Austrian Legal Research (USE THIS)\\n\\n```\\n1. JUSLINE.at → Gesetzestext im Volltext (immer treffer, direkt verlinkbar)\\n2. delegate_task mit web-Toolset → OGH-Rechtsprechung + Fachliteratur finden\\n3. Ergebnis als Markdown-Gutachten in /tmp/ speichern lassen\\n4. Gutachten lesen + Quellen prüfen, dann als Antwort formatieren\\n```\\n\\n### 1. JUSLINE.at — Primary Source for Gesetzestexte\\n\\nDirectly linkable, always returns current text. URL pattern:\\n- `https://www.jusline.at/gesetz/abgb/paragraf/829` → § 829 ABGB\\n- `https://www.jusline.at/gesetz/weg/paragraf/13` → § 13 WEG 2002\\n- `https://www.jusline.at/gesetz/abgb/paragraf/781` → § 781 ABGB (Schenkungsanrechnung)\\n\\nJUSLINE HTML is clean: strip `